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ABSTRACT 
Esophageal cancer ranks as the second most common cancer among black 
males in South Africa and patients often seek medical attention when the 
cancer has already reached advanced stages. Thus, there is a lot of work 
investigating factors associated with increased risk, biomarkers for early 
diagnosis as well as a search for suitable drugs to treat esophageal cancer. In 
this project, flavonoids were used on esophageal cancer cell lines to identify 
enzymes that are differentially expressed as well as to evaluate the 
flavonoids’ direct toxic effects on the cancer cells using ß-Naphthoflavone 
(BNF) on human esophageal cancer cell lines, WHCO1 and WHCO6. 
Differential expression of drug metabolising enzymes, CYP1A1, CYP1A2 
and CYP1B1 was also investigated. BNF showed a moderate 
antiproliferative activity in WHCO6 cells (IC50~ 10µM) and a weak activity 
in WHCO1 cells (IC50~25 µM). Thus, suggesting that esophageal cancer 
cells may be responsive to the treatment with BNF. BNF resulted in the 
differential expression of CYP1A1, CYP1A2, and CYP1B1.  These results, 
implicate CYP1 enzymes as potential therapeutic targets for esophageal 
cancer prevention. 
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CHAPTER 1: General introduction  
 
 1.1. Variation in xenobiotic metabolism 
Humans are continuously exposed to harmful xenobiotic compounds which if 
allowed to accumulate in their bodies could become toxic. Most of these 
xenobiotics require to be changed or biotransformed in order to be removed 
from the body. The biotransformation results in mainly detoxification of the 
xenobiotics but in some cases, metabolic activation occurs. Detoxication or 
biotranformation of xenobiotics is catalysed by enzymes that belong to gene 
superfamilies. Detoxification or metabolism of xenobiotics is classified into 
three phases, I, II and III. The phase I enzymes most of which are the 
cytochrome P450 (CYP) enzymes, catalyze the functionalization reactions 
resulting in more polar metabolites (Conney, 2003; Guengerich, 2004; Caro 
and Cederbaum, 2004; Coon, 2005; Kim and Guengerich, 2005). The phase II 
enzymes, such as the glutathione transferases, UDP glucuronosyltransferases 
and N-acetyl transferases, conjugate the phase I products with water-soluble 
endogenous metabolites such as glutathione, glucuronic acid, sulfate, cysteine 
or acetate, producing hydrophilic products that can be easily excreted 
(Burchell, 2003; Kuuranne et al; 2003). However, the phase I products are not 
always conjugated by phase II enzymes since the phase I products are often 
highly reactive metabolites and can bind to macromolecules such as proteins 
and nucleic acids (Figure 1.1), thus leading to cancer development 
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(Guengerich, 2000, Schwarz et al, 2001). Phase III metabolism is involved in 
the transport of the conjugated xenobiotics. 
 
Individuals with an imbalance in phase I, phase II enzyme and phase III 
activity may have a differential susceptibility to cancer. This project focuses on 
the CYP enzymes, since these enzymes play a major role in the toxicity and 
carcinogenesis of several xenobiotic compounds. 
 
Figure 1.1: A Simplified schematic showing the metabolism of xenobiotics. 
Xenobiotics entering the cell are metabolized by phase I enzymes and detoxified by phase II 
enzymes and their transport from the cells is facilitated by phase III enzymes. Phase I 
metabolites may either bind to macromolecules thus causing cancer or be conjugated with 
water-soluble endogenous molecules leading to excretion of these metabolites (Oyama et al, 
2003). 
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1.2. Cytochrome P450 (CYP) enzymes 
Cytochrome P450 (CYP) enzymes are a superfamily of hemoprotein 
monooxygenases that catalyze the oxidation of a wide variety of both 
endogenous compounds such as steroids, bile acids and fatty acids, and 
xenobiotic compounds including drugs, toxins and carcinogens (Caro and 
Cederbaum, 2004). The CYP enzymes or microsomal carbon monoxide 
binding pigments as they were initially called, were first discovered in the 
late 1950’s when Klingenberg identified a pigment in the rat liver that 
produced a unique spectrum ranging between 350 and 500nm upon 
reduction with carbon monoxide and gave an optical absorption peak at 
450nm (Klingenberg, 1958). A few years later, the hemoprotein nature of 
this pigment was identified and was then given the name cytochrome P450 
(Omura and Sato, 1964). 
 
CYP enzymes have been identified in all studied organisms, from bacteria to 
humans (Nelson et al, 2004). Fifty seven active (57) genes encoding 
cytochrome P450 and fifty eight(58) pseudogenes have been identified in 
humans to date (Nelson et al, 2004, Nelson, 2009).Using sequence homology, 
the CYP enzymes have been grouped into families and subfamilies and there 
are eighteen(18) families and fourty three(43) subfamilies currently known in 
humans (Nelson et al, 2004). The majority of CYP enzymes metabolize 
endogenous substrates in a highly substrate-specific manner (Lang et al, 2001; 
3 
 
Jinno et al, 2003; Nebert and Dalton, 2006) while others show some overlap in 
substrate specificity (Yamazaki et al, 2001; Shimada and Fujii-Kuriyama, 
2004; Mahadevan et al, 2007). Of the fiftyseven (57) CYP genes found in 
humans it is mostly the members of the CYP1, CYP2 and CYP3 families that 
are responsible for xenobiotic metabolism, while other CYP families only 
metabolize endogenous substrates (see Table 1.1.).The focus of this project 
will be on the CYP1 family of enzymes. 
 
Table 1.1.: Human CYP genes and their functions  
Family Members Main substrates/pathway 
 
CYP1 3 Subfamilies, 3 genes, 1 pseudogene Polyaromatic hydrocarbon 
CYP2 13 subfamilies, 16 genes,16 pseudogenes Caffeine and testosterone 
CYP3 1 subfamily,4 genes, 2 pseudogenes Xenobiotics, steroids 
CYP4 6 subfamilies, 11 genes, 10 pseudogenes Arachidonic acid  
CYP5 1 subfamily, 1 gene Thromboxane synthesis 
CYP7 2 subfamilies, 2 genes Cholesterol 7α-hydroxylation 
CYP8 2 subfamilies, 2 genes Prostacyclin synthesis 
CYP11 2 subfamilies, 3 genes Steroid biosynthesis 
CYP17 1 subfamily, 1 gene Steroid 17α-hydroxylation 
CYP19 1 subfamily, 1 gene Androgen aromatization 
CYP20 1 subfamily, 1 gene Unknown 
CYP21 2 subfamilies, 2 genes,1 pseudogene Steroid biosynthesis 
CYP24 1 subfamily, 1 gene Vitamin D degradation 
CYP26 3 Subfamilies, 3 genes Retinoic acid hydroxylation 
CYP27 3 subfamilies, 3 genes Steroid 27-hydroxylation 
CYP39 1 subfamily, 1 gene Cholesterol 
CYP46 1 subfamily, 1 gene Cholesterol 24-hydroxylation 
CYP51 1 subfamily, 1 gene, 3 pseudogene Cholesterol biosynthesis 
Data extracted from Lund et al, 1999 and Nelson, 1999 
4 
 
1.3. Human xenobiotic- metabolizing CYP1 enzymes 
The members of the CYP1 family are, CYP1A1, CYP1A2, CYP1B1 and a 
pseudogene (Nelson, 2009). The CYP1 enzymes have been studied extensively 
because of the major roles they play in chemical carcinogenesis. They catalyze 
the bioactivation of mostly polyaromatic hydrocarbons such as 
benz[a]anthracene, 7,12- dimethylbenz[a]anthracene, arylamines, and 
benzo(a)pyrene (BP) (Murray et al, 2001; Iwanari et al, 2002 ; Shimada and 
Fuji-kuriyama, 2004). The same substrates are also known to act as their 
inducers (Iwanari et al 2002; Guruge et al, 2009). The three CYP1 genes are 
expressed in a tissue specific manner (Jana et al, 2000; Murray et al, 2001; 
Coumoul et al, 2001; Iwanari et al, 2002;) and their transcriptional regulation 
is via the aryl hydrocarbon receptor complex (Nebert et al, 2004). The 
functions, tissue-specific expression and the regulation of these genes are 
discussed in the following sections. 
 
1.3.1. CYP1A1  
1.3.1.1. Gene structure 
The human CYP1A1 gene is located on chromosome 15 on loci 15q22-qter and 
is composed of seven exons and six introns (Jaiswal et al, 1987; Corchero et 
al, 2001). The CYP1A1 gene codes for a 2.8 kb mRNA and a protein of 512 
amino acids. Figure 1.2 shows a schematic of the gene organisation for 
CYP1A1. 
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Figure 1.2.: Schematic representation of the human CYP1A1 gene (adapted from 
Jaiswal et al, 1987 & Corchero et al, 2001). 
 
1.3.1.2. Metabolic reactions catalyzed by CYP1A1 
Human CYP1A1 is one of the key enzymes in the activation of pro-
carcinogenic polycyclic aromatic hydrocarbons (PAHs) (Guengerich, 1992; 
Shimada et al, 1992; Guengerich et al, 1999; Minsavage et al, 2004; Schwartz 
et al, 2007). PAHs are the major carcinogens found in the environment as 
pollutants. Prolonged exposure to PAH contaminated air has been associated 
with increased lung cancer risk (Boffetta et al, 1997). A classic example is the 
activation of benzo (a) pyrene (BP). BP is a PAH generated during incomplete 
combustion such as in cigarette smoke (Pfeifer et al, 2002). BP has been 
associated with immune suppression, birth defects and carcinogenesis (Miller 
and Ramos, 2001). CYP1A1 biotransforms BP to produce the ultimate 
carcinogen BP-7, 8-dihydrodiol-9, 10-epoxide (BPDE). BPDE can covalently 
bind to DNA thus causing guanine (G) to thymine (T) transversions (Tokiwa et 
al, 1993; Conney et al, 1994; Nebert et al, 2000; Schwarz et al, 2001; Pfeifer 
et al, 2002;). These transversions have been found to activate a number of 
transcriptional factors such as P53 (Blattner et al, 1999; Ueno et al, 1999). An 
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excessive amount of G to T transversions in the P53 gene has been associated 
with lung cancer. Figure 1.3 is a diagrammatic representation of a reaction 
catalysed by CYP1A1 and epoxide hydrolase (EH) resulting in the formation 
of the reactive metabolite, BPDE that covalently binds to DNA resulting in 
DNA damage and ultimately cancer. 
 
 
Figure 1.3: Metabolic activation of Benzo[a] pyrene into a carcinogenic Benzo 
(a) pyrene 7.8-diol-9, 10-epoxide. (Adapted from Kim et al, 1998) 
 
1.3.1.3. Tissue specific expression of CYP1A1 
CYP1A1 constitutive expression is very low in extrahepatic tissues (Shimada 
et al, 1992). However, high levels of this enzyme have been reported in almost 
every tissue studied, including vascular endothelium, smooth muscle cells, 
lung gastrointestinal tract, placenta, brain and others (Celander et al, 1997: 
Zhao et al, 1998; Ding and Kaminsky, 2003), only in the presence of an 
inducer. CYP1A1 is highly inducible by PAHs such as 2, 3, 7, 8-tetrachloro-
dibenzo-p-dioxin (TCDD) (Whitlock, 1999; Kim and Sheen, 2000; Chang et 
al, 2009), BP, 3-methylcholanthrene (3MC) and omeprazole (Whitlock, 1999; 
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Bowen et al, 2000; Rodriguez-Antona et al, 2000), through the aryl 
hydrocarbon receptor pathway (Whitlock, 1999; Denison and Nagy, 2003). 
Previous studies have shown CYP1A1 to be highly expressed in tumors 
compared with the surrounding normal tissues. For example, CYP1A1 was 
shown to be over expressed in ovarian cancer cells and esophageal tumors as 
opposed to normal cells (Murray et al, 1994; Nakajima et al, 1996; Leung et 
al, 2005). Recently, CYP1A1 was found to be highly expressed in oral 
squamous cell carcinoma after BP treatment (Hecht, 2003; Nagaraj et al, 2006; 
Chi et al, 2009). Therefore, CYP1A1 can be suggested as a target for novel 
chemotherapeutic agents (Mcfadyen et al, 2004; Rooney et al, 2004). 
 
1.3.1.4. CYP1A1 Polymorphisms 
Several CYP1A1 single nucleotide polymorphisms (SNPs) have been reported 
in the human population (http://www.cypalleles.ki.se/). Four common SNPS in 
CYP1A1 have been studied concerning their potential implications in the risk 
of breast cancer. These SNPs include T3801C, T3205C, A2455G and C2453A 
(Ambrosone et al, 1995; Taioli et al, 1995; Huang et al, 1999). CYP1A1 SNPs 
have also been reported to be associated with other cancer types such as 
prostate (Acevedo et al, 2003; Chang et al, 2003, Suzuki et al, 2003; Aktas et 
al, 2004; Quinones et al, 2006, Shaik et al, 2009), colorectal (Jin et al, 2011) 
esophageal (Zhuo et al, 2009), oral and pharyngeal (Varela-Lema et al, 2008), 
lung cancer (Shi et al, 2008, San Jose et al, 2010), ovarian, endometrial and 
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cervical cancer (Murata et al, 1998; Longuemaux et al, 1999; Esteller et al, 
1999; Goodman et al, 2001a; 2001b).  
 
1.3.2. CYP1A2 
1.3.2.1. Gene structure 
The human CYP1A2 loci is found on chromosome 15q22-qter and is composed 
of seven exons, six introns (Corchero et al, 2001), a 3.2 kb mRNA and a 
protein of 515 amino acids as shown in Figure 1.4 below. The CYP1A1 and 
CYP1A2 genes are separated by 23 kb and are orientated in opposite directions 
(Corchero et al, 2001). There is no open reading frame between these two 
genes, thus showing that they share a 5’-flanking region and share 80% amino 
acid sequence homology. 
 
Figure 1.4: A schematic representation of the human CYP1A2 gene (adapted 
from Corchero et al, 2001). 
9 
 
1.3.2.2. Metabolic reactions catalyzed by CYP1A2 
CYP1A2 is responsible for the oxidative metabolism of a wide range of 
therapeutic drugs such as theophylline, lidocaine, imipramine, verapamil and 
phenothrazines (Yamazaki et al, 2001; Daniel et al, 2002; Llibre et al, 2002). 
This enzyme is also involved in the activation of endobiotic compounds such 
as melatonin, estradiol and uroporphy rinogen (Nichols et al, 2003; Tsuchiya 
et al, 2005; Faber et al, 2005; Ma and Lu, 2007). In addition, CYP1A2 
metabolizes various carcinogenic compounds, such as heterocyclic and 
aromatic amines to reactive metabolites, leading to toxicity and cancer 
(Brosen, 1995; Guengerich et al, 1999; Van schaik, 2005; Ma and Lu, 2007). 
 
Aflatoxin B1 (AFB1) is a potent food carcinogen and has been reported as a 
causative agent in hepatocellular carcinoma (Kew, 2003; Sudakin, 2003;   
Williams et al, 2004). AFB1 on its own is not a potent toxin since it requires 
metabolic activation to exert its genotoxicity. CYP1A2 catalyzes the 
biotransformation of AFB1 to the highly reactive AFB1-8, 9-epoxide (McLean 
and Dutton, 1995; Guengerich et al, 1998) (Figure 1.5.). This epoxide is a 
mixture of both the exo- and endo-8, 9-epoxide (Ueng et al, 1995). Only the 
exo-8, 9-epoxide has been reported to have genotoxic characteristics 
(Guengerich et al, 1998). Exo-8, 9-epoxide is highly unstable and binds to 
guanine bases in DNA thus forming aflatoxin-N7-guanine (Guengerich, 2001; 
Nayak et al, 2001). The aflatoxin-N7-guanine has been reported to be capable 
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of forming guanine to thymine transversion mutations in DNA (Bailey et al, 
1996) (Figure 1.5). 
 
 
Figure 1.5: Metabolic activation of Aflatoxin B1 to AFB1 –8, 9-epoxide 
leading to the formation of AFB –DNA adduct (AFB –N71 1 -guanine) (Chou and 
Chen, 1997). 
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1.3.2.3. Tissue specific expression of CYP1A2 
Human CYP1A2 is constitutively expressed in the liver (Mckinnon et al, 1991; 
Schweikl et al, 1993; Landi et al, 1999), thus accounting for 13% of the total 
CYP in this organ. However, a few studies have reported the expression of this 
gene in other organs such as the lung (Macé et al, 1998; Wei et al, 2001; 
Bernauer et al, 2006), esophagus (Lechevrel et al, 1999), brain (Bhagwat et al, 
2000), prostate (Williams et al, 2000) and gastrointestinal tract (Tatemichi et 
al, 1999). The constitutive level of expression of the CYP1A2 gene is increased 
by exposure to PAHs from cigarette smoke and TCDD via the Aryl 
hydrocarbon receptor/Aryl nuclear translocator (AHR/ARNT) complex (Shen 
et al, 1994; Hankinson et al, 1995; Landi et al, 1999). 
 
1.3.2.4. CYP1A2 polymorphisms  
Several CYP1A2 polymorphisms have been reported in the past few years 
(http://www.cypalleles.ki.se). These polymorphisms are associated with 
individual differences in CYP1A2 activity (Saruwatari et al, 2002; Zhang et al, 
2007). It has been demonstrated that the CYP1A2 SNP G3860A is associated 
with decreased enzyme inducibility in Japanese smokers (Nakajima et al, 
1999). The CYP1A2 SNP C163A was also reported to be associated with 
higher enzyme inducibility in white smokers (Sachse et al, 1999). In a recent 
study the CYP1A2 haplotype (T739G, C729T, and C163A) was reported to be 
linked with decreased enzyme activity in Ethiopian non-smokers (Aklillu et al, 
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2003). These interindividual differences influence individual susceptibility to 
cancer risk caused by procarcinogens and the therapeutic efficacy of drugs. 
Recently, low inducibility of CY1A2 polymorphism was reported to be 
associated with a high risk of myocardial infarction (Cornelis et al, 2004). 
 
1.3.3. CYP1B1 
1.3.3.1. Gene structure 
The human CYP1 gene family was initially thought to consist of CYP1A1 and 
CYP1A2 only. It was only in 1994 that a new member of the CYP1 gene 
family, CYP1B1, was discovered. This gene was induced in human 
keratinocyte cell line treated with tetrachloro-dibenzo-p-dioxin (Sutter et al, 
1994). The CYP1B1 cDNA was cloned to facilitate the characterization of the 
protein. Nucleic acid and amino acid sequence analysis revealed ~40% 
homology of CYP1B1 with CYP1A1 and CYP1A2. There are various distinct 
properties that separate CYP1B1 from CYP1A1 and CYP1A2. CYP1B1 gene is 
located on position 2p21-22, spanning approximately 12 kilobases (kb) of 
DNA and contains three exons and two introns (Tang et al, 1996). Although it 
has the simplest gene structure, CYP1B1 is one of the largest known human 
CYPs in terms of the mRNA size and number of amino acids. CYP1B1 has a 
5.2kb mRNA with an open reading frame beginning at the 5’ end of the second 
exon (Murray et al, 2001). The predicted protein sequence of this CYP is 543 
amino acids (Figure 1.6) and this differs with other CYPs which have their 
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open reading frames beginning in exon 1 (Murray et al, 2001). Figure 1.6 
below shows the schematic organisation of the CYP1B1 gene. 
 
Figure 1.6: A schematic representation of the human CYP1B1 gene (adapted 
from Murray et al, 2001). 
 
1.3.3.2. Metabolic reactions catalyzed by CYP1B1 
The human CYP1B1 activates many structurally diverse environmental 
procarcinogens, such as PAHs, heterocyclic and aryl amines, as well as the 
nitroaromatic hydrocarbons (Shimada et al, 1996; Kim et al, 1998; 
Guengerich, 2000; Guengerich et al, 2003). CYP1B1 also detoxifies cancer 
drugs such as flutamide and docetaxel, and this reduces their cytotoxic 
potential and effectiveness (Rochat et al, 2001; MacFadyen et al, 2001; 
Bournique and Lemarie, 2002). CYP1B1 has also been found to be effective in 
activating aflatoxin B1 to its mutagenic metabolite (Crespi et al, 1997). When 
expressed in S.cerevisiae, the human CYP1B1 was found to metabolize a 
dietary heterocyclic amine, 2-amino-1 methyl-6-phenylimidazo [4, 5-b] 
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pyridine which has been associated with breast and colon cancer (Crofts et al, 
1997). 
 
In addition to its role in procarcinogen activation, CYP1B1 is also a key 
enzyme involved in the production of potentially carcinogenic estrogen 
metabolites. Estrogens have various biological effects, such as female sexual 
differentiation and development, and arterial vasodilation, the maintenance of 
bone density and neuroprotective actions. However, prolonged exposure to 
estrogens has been associated with breast cancer and endometrial cancer (Pike 
et al, 1993; Jordan, 2000; and Liehr, 2000). Xenoestrogens, such as oral 
contraceptives and drugs for hormone replacement therapy are also associated 
with breast cancer risk through their estrogenic properties  
 
17-β estradiol (E2) is the most common steroidal estrogen present in women. 
The principal source of this estrogen is from pre-menopausal females, ovary 
and adrenal glands .CYP1B1 encodes for an enzyme that metabolizes E2 to 
catechol estrogens 4-hydroxyestradiol (4-OHE2) and 2-Hydroxy estradiol (2-
OHE2) (Figure 1.7). This enzyme usually produces higher levels of 4-OHE2 
than 2-OHE2 (Yager and Liehr, 1996; Hayes et al, 1996; Spink et al, 1997; 
Cavalieri et al, 1997; Badawi et al, 2001; Cavalieri and Rogan, 2004). The 4-
OHE2 gets oxidized to E2-3, 4-Quinone which readily reacts with DNA thus 
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causing damage to the DNA (Nutter et al, 1991; Nutter et al, 1994; Cavalieri et 
al, 1997) (Figure 1.7). High levels of 4-OHE2 have been detected in human 
uterine myometrium, benign uterine leiomyoma (Liehr et al, 1995), as well as 
in benign and malignant mammary tumors (Lemon et al, 1992; Liehr and 
Ricci, 1996). Human breast cancer tissues have been shown to have 
significantly higher levels of 4-OHE2 than normal breast tissues (McKay et al, 
1995; Liehr and Ricci, 1996; Murray et al, 1997).The catechol estrogen 4-
OHE2 has also been shown to be carcinogenic in animal models (Kristensen 
and Borresen-Dale, 2000; Hanna et al, 2000). CYP1B1 is therefore one of the 
risk factors for breast cancer because of the role it plays in steroid metabolism. 
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 Figure 1.7: Metabolic activation of estradiol and the formation of non-
carcinogenic 2-methoxyestradiol and the carcinogenic 4-hydroxyestradiol. 
Abbreviations used CYP1B1 (Cytochrome P450 1B1), COMT (Catechol O-
methyltransferase) (adapted from Chun and Kim, 2003).  
 
1.3.3.3. Tissue specific expression of CYP1B1  
The human CYP1B1 mRNA and protein are constitutively expressed in 
extrahepatic tissues such as the ovaries, testes, adrenal glands, breast, uterus 
and prostate, but are poorly expressed in the liver, kidney and lung tissues 
(Shimada et al, 1996; Hakkola et al, 1997 and Tang et al, 1999). One of the 
most significant discoveries regarding CYP1B1 expression is its high 
frequency of expression in various types of tumors compared to the 
corresponding normal tissues (Murray et al, 1997; Cheung et al, 1999; 
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McFadyen et al, 1999). For example, the expression of CYP1B1 was detected 
in breast tumors, but not in normal breast tissues (Huang et al, 1996; 
Kaminsky and Spivack, 1999). In one study, CYP1B1 was found to be over 
expressed in prostate tumors when compared to the normal prostate tissues 
(Finnström et al, 2001; Chaib et al, 2001; Carnell et al, 2004). Together these 
findings implicate CYP1B1 as a potential therapeutic target for reducing the 
development of a wide variety of cancers and that this CYP may play a major 
role in anticancer drug resistance (McFadyen et al, 2001; Rochat et al, 2001). 
 
1.3.3.3. CYP1B1 polymorphisms 
Six different polymorphisms of the CYP1B1 gene have been reported and four 
of these result in amino acid substitutions (Bailey et al, 1998; Stoilov et al, 
1998; Mitrunen and Hirvonen, 2003). Two of these amino acid substitutions 
are encoded by exon 3, which encodes the heme-binding domain, at codon 453 
Asn is substituted with Ser (Asn453Ser) (Bailey et al, 1998). The other amino 
acid substitutions are encoded by exon 2 (Stoilov et al, 1998), and they 
include, Arg48Gly and Ala119Ser. 
 
The CYP1B1 polymorphisms have been reported to have an association with 
breast or endometrial cancer risk (Bailey et al, 1998; Zheng et al, 2000; De 
vivo et al, 2002; Kocabas et al, 2002; Lee et al, 2003 and Sasaki et al, 2003; 
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Ozbek et al, 2010). These polymorphisms have also been found to lead to 
alterations in estrogen metabolism, thus causing 2 to 3 fold higher catalytic 
activity than the wild type enzyme (Shimada et al, 1999 and Hanna et al, 
2000). For example, the Leu432Val polymorphism was reported to have the 
highest effect on the catalytic properties of the enzyme since the Val432 
variant displayed three-fold higher 4-hydroxylase activity than the Leu432 
variant (Li et al, 2000; Hanna et al, 2000 and Aklillu et al, 2002). Other studies 
also showed that Val432 variant is associated with higher 4-hydroxyestradiol: 
2-hydroxyestradiol and 4-hydroxyestrone: 2-hydroxyestrone ratios than the 
Leu432 variant (Shimada et al, 1999). Higher catalytic activities towards 
estrogen metabolism have also been reported for the Gly48, Ser119, and 
Ser453 polymorphisms (Hanna et al, 2000). 
 
1.3.4. The Aryl hydrocarbon receptor 
1.3.4.1. Gene structure  
The Aryl hydrocarbon receptor (AHR) is a ligand activated basic helix-loop-
helix (bHLH) protein that belongs to the Per-Arnt-Sim (PAS) family of 
transcription factors (Schmidt and Bradfield, 1996). It regulates the expression 
of human CYP genes (Quattrochi et al, 1994; Tang et al, 1996; Whitlock, 
1999; Nebert et al, 2000) as well as some Phase II metabolizing enzymes 
(Hankinson, 1995; Schimidt and Bradfield, 1996; Hahn, 2002). The AHR was 
first discovered in the livers of the C5BL/6 mice treated with TCDD (Bradfield 
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et al, 1991). In humans, this receptor encompasses 47,146 nucleotides and is 
located on chromosome 7 at location 7p15-21 (Micka et al, 1997). The human 
AHR consists of 11 introns and 12 exons, which encode an mRNA of 5.483 
nucleotides thus giving rise to a protein with 848 amino acids (Harper et al, 
1991). An illustration on the structure of how the gene is organised is given in 
Figure 1.8 below. 
 
Figure 1.8: A schematic representation of the human AHR gene (adapted from 
Harper et al, 1991). 
 
1.3.4.2. The AHR pathway 
In its inactive form, the AHR is localized in the cytoplasm as a complex with a 
dimmer of heat shock proteins (HSP90), and one molecule of the AHR 
interacting protein (AIP) (Perdew, 1988; Holmes and Pollenz, 1997; Petrulis 
and Perdew, 2002; Hollingshead et al, 2004; Bock and Kohle, 2006), which 
are responsible for the AHR folding and stabilization (Gu et al, 2000). 
Halogenated aromatic hydrocarbons and polycyclic aromatic hydrocarbons 
such as polychlorinated biphynyls, BP and polychlorinated dibenzo-p-dioxins 
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are the most common classes of the AHR ligands known (Denison et al, 1998; 
Denison and Heath-pagliuso, 1998). AHR ligands enter the cell by passive 
diffusion, where they encounter and bind to the AHR. Upon ligand binding, 
the AHR dissociates from the associated proteins and form a ligand-AHR 
complex. This complex translocates into the nucleus where it forms a 
heterodimer with the aryl nuclear translocator (ARNT) (McGuire et al, 1994; 
Goldberg, 1997; Heid et al, 2000; Fujii-Kuriyama and Mimura, 2005). The 
liganded AHR-ARNT heterodimer binds to specific regions of DNA known as 
xenobiotic response elements (XRE) thus regulating the expression of 
numerous genes, including CYP1A1, CYP1A2, and CYP1B1, in a positive or 
negative way as shown in Figure 1.9 (Hankinson, 1995; Nebert et al, 2000; 
Mimura and Fujii-Kuriyama, 2003; Okey et al, 2005; Ramadoss et al, 2005). 
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Cytoplasm
Figure 1.9: Outline of the function of aryl hydrocarbon receptor (AHR) as a 
ligand-activated transcription factor. AHR, Aryl hydrocarbon receptor; ARNT, AH-
receptor-nuclear-translocator; CYP 1, Cytochrome P450 1; HSP90, heat shock protein 90 
(shown in yellow), AIP, AHR interacting protein (shown in black); L, Ligand; XRE, 
Xenobiotic responsive element (adapted from Pollenz, 2002) 
 
1.3.4.3. Regulation of the AHR pathway 
The AHR signalling may be down-regulated by several mechanisms; one of 
which is through the degradation of AHR protein through the ubiquitin-
proteasome pathway (Pollenz, 2002). This pathway involves the binding of 
ubiquitin to the target protein (Pahl and Baeuerle, 1996; Tanaka, 1998, 
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Ciechanover et al, 2000; Kornitzer and Ciechanover, 2000). The ubiquitinated 
protein is then degraded rapidly by the 26S proteasome (Pahl and Baeuerle, 
1996; Tanaka, 1998, Ciechanover et al, 2000; Kornitzer and Ciechanover, 
2000). 
 
The ubiquitin proteasome degradation pathway plays a role in the regulation of 
the AHR signal transduction pathway (Pollenz, 1996; Pollenz et al, 1998; 
Giannone et al, 1998; Pollenz and Barbadour, 2000; Ma and Baldwin, 2000). 
The degradation of AHR through the ubiquitin proteasome pathway can occur 
either in the cytosol or nucleus (Pollenz, 2002). For AHR degradation to occur 
the AHR/ARNT complex dissociates from the XRE and the ARNT, 
ubiquinated in the nucleus and gets degraded (Pollenz et al, 1994; Pollenz, 
1996; Pollez, 2002) (Figure 1.9). Alternatively, after dissociating from the 
XRE and ARNT, AHR can be exported from the nucleus, ubiquinated in the 
cytoplasm and gets degraded by the 26S proteasome (Pahl and Baeuerle, 1996; 
Tanaka, 1998; Davarinos and Pollenz, 1999; Ciechanover et al, 2000; 
Kornitzer and Ciechanover, 2000; Pollenz, 2002). 
 
The other mechanism responsible for AHR downregulation involves the aryl 
hydrocarbon receptor repressor (AHRR) which acts as a negative regulator of 
the AHR function by competing with AHR for ARNT (Gradin et al, 1993; 
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Mimura et al, 1999; Gradin et al, 1999). A liganded AHR in a heterodimer 
with ARNT activates the expression of the AHRR gene (Mimura et al, 1999). 
The expressed AHRR inhibits the activity and binds to the ARNT, thus 
forming the AHRR-ARNT heterodimer (Gradin et al, 1993; Mimura et al, 
1999; Haarmann-Stemmann and Abel, 2006). This heterodimer binds to the 
XREs in DNA. 
 
1.3.4.4. Association of AHR polymorphisms with human diseases 
Human genetic variation has been widely studied for phase I and phase II 
metabolizing enzymes (Nebert et al, 1999; Park et al, 2000; Kalow, 2001; 
Ingelman-Sundberg, 2001; Lin and Lu, 2001; Miller and Kumar, 2001; Xie et 
al, 2001). Most of the sequence variants that have been reported in human 
AHR protein are due to SNPs. 
 
An association of SNPs with complex diseases such as cancer has been 
reported in most human genes; however, no striking effects of AHR SNPs on 
human health have been reported. For example, human exposure to dioxin-like 
compounds such as TCDD has been shown to cause chloracne, which is a 
severe skin disorder (Guo et al, 1999; Geusau et al, 2001). However, in one 
study, no association between the codon 554 polymorphism and chloracne was 
found in Caucasian population (Wanner et al, 1999). To date, no study has 
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reported a link between cancer and AHR polymorphism. For example, in 
previous studies there was no link found between the polymorphism associated 
with position 554 and lung cancer risk in Japanese smokers (Kawajiri et al, 
1995). Cauchi et al, (2001), further confirmed this when he reported no link 
between the G459A polymorphism and lung cancer risk. Recently, Zhang et 
al, (2002) also found no association of the codon 554 polymorphism with 
bladder cancer risk in Chinese population. 
 
1.4. Cancer Chemotherapy 
Each year an estimated 11 million people are diagnosed with cancer worldwide 
(Ferlay et al, 2004). Current chemotherapeutic options for cancer include drugs 
most of which have been shown to possess severe side effects (Marsh and 
McLeod, 2007). Due to this, there is a focus towards new chemotherapeutic 
agents that show limited toxicity to normal tissue as well as limited side 
effects. 
 
Flavonoids represent a large class of phenolic compounds present in plants. 
These compounds have often been associated with cancer prevention (Messina 
et al, 2006; Verheus et al, 2007; Arroo et al, 2008). In recent studies, their 
interaction with CYPs has been of particular interest. Flavonoids have been 
shown as inhibitors of CYP1A and CYP1B1 enzyme activity (Kim et al, 2005; 
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Chang et al, 2006) thus blocking the activation of procarcinogens into 
crcinogens (Shimada and Kuriyama, 2004). In the current study, the effect of 
β-Naphthoflavone (BNF), a synthetic derivative of a naturally occurring 
flavonoid, on CYP1 expression was investigated. This is the first study that 
reports the effect of BNF on the expression of CYP1 enzymes in esophageal 
cancer cells WHCO1 and WHCO6 cells.  
 
1.5. AIMS 
1. To evaluate the antiproliferative activity of a synthetic flavonoid, β-
Naphthoflavone, on esophageal cancer cells, WHCO1 and WHCO6 using 
MTT cell viability assay  
 
2. To investigate the effect of β-Naphthoflavone on the expression of the 
CYP1 proteins (CYP1A1, CYP1A2 and CYP1B1) using Western blot 
analysis. 
 
3. To determine whether the regulation of CYP1A1, CYP1A2 and CYP1B1 
is associated with the AHR pathway by using Western blot analysis. 
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CHAPTER 2: The model 
 
2.1. Introduction 
Cancer of the esophagus is the ninth most common cancer worldwide and 
recent evidence shows that its incidence is rising (Munoz, 1993; Parkin et al, 
2001a; 2001b). Exposure to foreign chemical compounds is one of the main 
risk factors of this disease. Unfortunately, the hydrophobicity of these 
compounds is often an obstacle to their elimination. Hence, these compounds 
may accumulate to toxic levels, unless they are transformed to water soluble 
molecules that can be easily excreted. That is one of the reasons that  
Cytochrome P450 (CYP) enzymes were the chosen research topic since these 
enzymes play a major role in the oxidative metabolism of a wide range of toxic 
chemical compounds (Conney, 2003; Guengerich, 2004; Caro and Cederbaum, 
2004; Coon, 2005; Kim and Guengerich, 2005). A characteristic of CYP 
enzymes is their inducibility by chemical compounds thus allowing the cell to 
adapt to changes in its chemical environment. The aim of the current study is 
to determine the effect of ß-naphthoflavone (BNF), a synthetic derivative of a 
naturally occurring flavonoid, on the expression of CYP enzymes in 
moderately differentiated esophageal cancer cell lines, WHCO1 and WHCO6. 
First, an assessment of the BNF potency against the target cells was done in 
order to rule out the effect of toxicity. One of the obstacles in this assessment, 
however, was the poor solubility of BNF in the culture media; therefore, 
dimethyL sulfoxide (DMSO) was used to dissolve BNF. 
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DMSO was successfully used to increase the solubility of BNF, however, 
because DMSO has been reported to interact with cell membranes and affect 
metabolism in other cells (PenninCKx et al, 1983; Brayton, 1986), an 
experiment was done to determine the cytotoxic effects of DMSO alone on 
WHCO1 and WHCO6 cell lines. The 3-(4,5-Dimethylthiazol-2-yl)-2, 5-
Diphenyltetrazolium bromide (MTT) assay was used to detect cytotoxicity or 
cell viability following exposure to DMSO according to the method of 
Mosmann et al, (1983). Briefly, the MTT assay measures the ability of viable 
cells to convert a soluble yellow tetrazolium salt (MTT) into insoluble purple 
formazan crystals by the mitochondrial dehydrogenase enzymes. The crystals 
are insoluble in aqueous solutions but can be dissolved in acidified 
isopropanol. The absorbance of the dissolved formazan solution is then 
quantified by measuring at a wavelength of between 500 and 600nm using a 
spectrophotometer. An increase in cell number leads to an increase in the 
amount of MTT formazan formed and an increase in absorbance (Mosmann et 
al, 1983). 
 
The aim was to determine the DMSO concentration with the least effect on the 
viability of WHCO1 and WHCO6 cells and subsequently dissolve BNF in that 
least toxic DMSO concentration. This study will also be of help in future to use 
these cell lines to study different types of proteins and their interaction in 
esophageal cancer. 
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2.2. Materials and Methods 
2.2.1. Cell line and Cell Culture 
The human esophageal squamous carcinoma cell (HOSCC) lines WHCO1 and 
WHCO6 were derived from moderately differentiated squamous cell 
carcinoma tumors (Veale and Thornley, 1989). These cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) containing 4.5 g/L glucose, L-
alanyl-glutamine, sodium bicarbonate and pyridoxine, HCl (Sigma), 
supplemented with 10% heat inactivated fetal bovine serum (FBS) (Sigma) at 
37ºC, 95% humidity and 5% CO2. 
 
2.2.2. Cell treatment 
WHCO1 and WHCO6 cells at 60-80% confluence were harvested and plated 
at a density of 5000 cells per well in 96-well flat-bottomed plates in a final 
volume of 90µl DMEM containing 10% FBS. The cells were left to grow at 
37ºC and 5% CO2 atmosphere for 24 hours. The cells were then treated with 
DMSO at different concentrations (0%, 0.2%, 1%, 2.5%, and 5% v/v) in 
triplicate. To make a final volume of 100µl, DMEM (Sigma) containing 10% 
FBS was added. The cells were incubated at 37ºC and a 5% CO2 atmosphere 
for 24 hours. 
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2.2.3. MTT Cell Viability Assay 
The MTT cell viability and proliferation assay was done by following the 
method previously used by Mosmann et al, (1983). To each well 10µl of MTT 
solution (5mg/ml) (Appendix 1.1) was added and the cells were incubated at 
37ºC for 4 hours. After 4 hours 100µl of the solubilisation reagent (10% SDS 
in 0.01M HCl) was added to each well and incubated at 37ºC and a 5% CO2 
atmosphere for 16 hours. The absorbance was read with an iMarkTM microplate 
reader (Bio-Rad) at a wavelength of 590nm. The percentage of cell 
viability/DMSO cytotoxicity was calculated relative to control cells designated 
as 100% viable cells. This experiment was repeated 3 times. 
 
2.2.4. Statistical Analysis 
The results were expressed as means ± standard deviations (SD) for at least 
three independent experiments. Significant differences were determined using 
one way analysis of variance (ANOVA) followed by Tukey’s post comparison 
test (Graphpad prism 5) (Appendix 2-3). A probability level of P<0.05 was 
considered significant. 
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2.3. Results 
 
MTT cell viability test was used to determine the effect of DMSO on the 
viability of two esophageal cancer cell lines WHCO1 and WHCO6 after 24- 
hour incubation. Figure 2.1 shows the percentage cell viability in relation to 
DMSO concentration after 24-hour incubation. The results showed a gradual 
decrease of cell number with an increase in DMSO concentration. It was also 
found that there was a significant difference (P<0.05) in the toxic effect of 
DMSO at concentrations from 0-5% (v/v). At higher DMSO concentrations, 
the number of cells decreased drastically when compared to the lower DMSO 
concentrations. Figure 2.1 below shows the effects of varying concentrations 
of DMSO on the two cell lines, WHCO1 and WHCO6. 
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 A B  
Figure 2.1: The effect of DMSO on cell viability. WHCO1 (A) and WHCO6 (B) cells were 
incubated with increasing concentrations of DMSO for 24 hours. Cell viability was measured by 
the MTT assay and the percentage of viable cells relative to the control was calculated for each concentration. 
Error bars represent the mean ± S.D. from three independent experiments. Statistical differences were 
determined with one-way analysis of variance (ANOVA) followed by Tukey’s multiple comparison test (Graph 
pad prism 5).  
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2.4. Discussion and Conclusion 
 
Compounds that are poorly soluble in water or culture media are often 
encountered during the process of drug discovery. Solvents are thus used to 
increase the solubility of such compounds. DMSO is an amphipathic molecule 
consisting of a polar domain and two non-polar methyl groups thus making it 
to be easily soluble in both aqueous and organic media. DMSO is one of the 
most common solvents that have been used to dissolve hydrophobic 
compounds. However previous studies have shown DMSO to penetrate 
through cells, thus influencing the structure and conformation of proteins and 
cell membrane, thus affecting cell viability (PenninCKx et al, 1983; Brayton, 
1986). Therefore, in experiments whereby DMSO is to be used as a solvent, it 
is always important to determine the effect of only the solvent and use a 
correction factor when the toxicity of another compound is calculated. 
 
DMSO was used as a solvent to dissolve the compound of interest BNF. In 
order to determine what concentration of DMSO was suitable to dissolve BNF 
and had least effect on the viability of WHCO1 and WHCO6 cells, different 
concentrations of DMSO were added to the two cell lines and the effect was 
examined using the MTT cell viability test. 
 
The effects of DMSO on cell viability have been studied in a large number of 
cell types, but variable results have been reported in these studies. For 
example, most studies have shown insignificantly lower or no effect on cell 
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viability after 24- hour treatment with 0.1% DMSO (Skupinska et al, 2007; 
Maruyama et al, 2007; Tampio et al, 2008). Studies with lymphoma cells have 
shown DMSO concentrations of 1-2% to prevent apoptosis (Lin et al, 1995). 
Other cell types appear to be more resistant to the cytotoxic effects of DMSO, 
for example, DMSO concentration of 10% had no cytotoxic effects on 
Caco2/Tc7 cells (Da Violante et al, 2002). In this study, 5% (v/v) DMSO 
which is the highest DMSO concentration which was used was found to have 
high cytotoxic effects when compared to the other concentrations, causing a 
reduction of cell viability to 12% in WHCO1 and 40% in WHCO6 cells 
(Figure 2.1). Only treatment with 0.2% v/v DMSO gave similar percentage 
viability to that of the control cells in both cell lines. However, DMSO was 
found to be more toxic in WHCO1 cells than in WHCO6 cells in all the 
different concentrations , this can be seen on figure 2.1 where the less toxic 
DMSO concentration, 0.2% (v/v), reduced cell viability to 90% in WHCO1 
cells (Figure 2.1A) and 98% in WHCO6 cells (Figure 2.1B). These results are 
in agreement with previous studies which also showed 0.2% (v/v) DMSO to be 
a safe concentration for use in tissue culture since DMSO at this concentration 
seems to cause less or no effect in cell viability (Hukkanen et al, 1999; Gelardi 
et al, 2001; Nishi et al, 2002). 
 
In summary, the results observed here indicate that 24 hour treatment with 
DMSO concentrations of 5% (v/v) have higher cytotoxic effects on esophageal 
cancer cell lines WHCO1 and WHCO6 , with WHCO1 cells being more 
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sensitive to the cytotoxic effects of DMSO at both higher and lower DMSO 
concentrations when compared to the WHCO6 cells. The results show that at 
concentrations up to 0.2% (v/v), DMSO had no cytotoxic effects on WHCO1 
and WHCO6 cells; hence, BNF was dissolved in 0.2% DMSO for use in 
subsequent experiments. Although concentrations lower than 0.2% were 
shown to be associated with much reduced toxicity, they were not good in 
dissolving the required drug. 
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CHAPTER 3: The value of BNF as an 
antiproliferative agent for esophageal 
cancer cells 
 
3.1. Introduction 
 
Prognosis of esophageal cancer is poor with an overall 5-year survival rate of 
less than 10%. There are many factors that have been associated with increased 
risk of developing esophageal cancer and these include, gender, ethnicity, 
environmental factors as well as genetic factors. Therefore, early detection and 
search for potential anticancer compounds is important in the control of this 
carcinoma. Studies have revealed a large variety of phyto-chemicals that have 
proven successful against a wide range of cancers. In particular, flavonoids 
have been shown to influence a variety of biological functions including 
inhibition of cancer cell growth (Marchand et al, 2000). 
 
The chemical structure of flavonoids is derived from a heterocyclic 
hydrocarbon, chromane, by substituting its ring C with phenyl group (ring B) 
in either position 2 or 3 (Gary, 2003) (Figure 3.1). Flavonoids are classified as 
flavonols, flavones, flavanols, flavanones, anthocyanidins and isoflavonoids 
based on the differences in the chemical structure of the heterocyclic C ring, 
the number and position of the double bonds and hydroxyl(OH) groups 
(Kozikowski et al, 2003). It has been reported that flavonoids with 4-6 OH 
groups often act as strong antioxidants, while those with more or fewer OH 
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groups show low or no antioxidant activities (Rice-Evans et al, 1995; Rice-
Evans et al, 1996). 
 
 
Figure 3.1: Different types of flavonoid structures (adapted from Hodek et al, 2002). 
 
Compounds of flavonoid structure have shown their antiproliferative effects by 
delaying or reversing the process of carcinogenesis. They achieve this by 
protecting membranes, proteins and DNA from oxidative damage, by 
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scavenging hydroxyl radicals, superoxide anion radicals and lipid 
peroxyradicals (Chan et al, 1998, Doostdar et al, 2000, Henderson et al, 2000). 
They also inhibit enzymes implicated in procarcinogenesis and detoxification 
of xenobiotics (Bravo, 1998). Considering the antiproliferative activity of some 
flavonoids on certain tumor cells and due to lack of such knowledge on 
esophageal cancer cells, in the current study the antiproliferative activity of a 
synthetic derivative of a naturally occurring flavonoid, β-Naphthoflavone 
(BNF) on WHCO1 and WHCO6 cells was evaluated. This study may provide 
some new knowledge about esophageal cancer therapy. 
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3.2. Materials and Methods 
3.2.1. Cell line and Cell Culture 
WHCO1 and WHCO6 cells were maintained by following the protocol 
described in chapter 2 (Section 2.2.1) 
 
3.2.2. Cell treatment 
At least three independent studies were conducted in triplicates each time. 
WHCO1 and WHCO6 cells at 60-80% confluence were harvested and plated 
at a density of 5000 cells per well in 96-well flat-bottomed plates. α-
Naphthoflavone (ANF) and Benzo pyrene (BP) were used as negative controls 
and 3-Methylcholanthrene(3MC) was used as a positive control in order to 
assess the validity of the MTT cytotoxicity assay. Stock solutions of BNF, 
ANF, BP and 3MC (50 Mm and 10 Mm) were dissolved in DMSO and added 
to the media to give final concentrations of 5, 10, 25, 50 and 100 µM BNF (in 
each case the final concentration of DMSO in media was 0.2%) in a final 
volume of 100 µl. Cells treated with the solvent alone (0.2% DMSO) also 
acted as the negative control.. The cells were treated with BNF, ANF, BP and 
3MC at these concentrations for 24, 48 and 72 hours and incubated at 37ºC, 
95% humidity and 5%CO2 
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3.2.3. MTT Cell Viability Assay 
After the incubation period, 10µl of the MTT (final concentration of 0.5 
mg/ml) (Appendix 1.1) was added to each well and incubated for 4 hours at 
37ºC, 95% humidity and 5% CO2. 100µl of the solubilization solution (10% 
SDS in 0.01M HCL) was added to each well. The plate was incubated 
overnight at 37ºC, 95% humidity and 5% CO2. The absorbance of the 
formazan produced by the viable cells was measured for each well at a 
wavelength of 590nm using an iMARKTM microplate reader (Bio-Rad). The 
percentage of cell viability was calculated relative to control cells (0.2% 
DMSO treated cells) designated as 100% viable cells.   
 
3.2.4. Determining the median inhibition concentration (IC ) 50
To assess the effectivity of a compound in inhibiting cell proliferation, an IC50, 
which is a concentration at which 50% of cell growth is inhibited, is usually 
calculated. The IC50 for BNF was calculated after treatment in WHCO1 and 
WHCO6 cells (Appendix 6). 
 
3.2.5. Statistical Analysis 
The results were expressed as means ±standard deviations (S.D) for at least 
three independent experiments. Significant differences were determined using 
one-way analysis of variance (ANOVA) followed by Tukey’s multiple 
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comparison test (Graphpad prism 5) (Appendix 4-5) A probability level of 
p<0.05 was considered significant.    
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3.3. Results 
3.3.1. The antiproliferative activity of BNF against WHCO1 and WHCO6 
esophageal cancer cells 
To evaluate the effect of BNF, WHCO1 and WHCO6 cells were treated with 
increasing concentrations of BNF for 24, 48 and 72 hours. Cell viability was 
measured using the MTT assay. To assess the validity of the MTT cell viability 
assay BP and ANF were used as negative controls and 3MC was used as a 
positive control. The assay lasted for 72 hours because other situations may 
arise at longer incubation periods, such as quiescence, metabolic stopping or 
induction of apoptosis.  
 
BNF showed the biggest antiproliferative effects against WHCO1 and 
WHCO6 esophageal cancer cells which was dose and time dependent (see 
Figure 3.2 and 3.3). However, the effects of BNF seemed to diminish overtime 
in the WHCO1 cell while in the WHCO6 cell line the effects increased with 
time. 
 
The 3MC, used as a positive control in this study was associated with a 
significant (P< 0.05) reduction in proliferation of both WHCO1 and WHCO6 
and its effects were also time and dose dependent. However, compared to the 
effect of BNF, 3MC was less potent against the proliferation of both WHCO1 
and WHCO6 cells. 
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BP and ANF were used as negative controls. These two compounds seemed 
not to have any activity against the proliferation of both WHCO1 and WHCO6 
cells. The results demonstrate that with increasing concentrations of BP and 
ANF from 5µM to 25µM the percentage of cell proliferation increased 
progressively after 24-48 hour of exposure. It was only after 72h of 100µM BP 
and ANF exposure that cell proliferation was inhibited to below 80% (Figure 
3.3). 
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Figure 3.2: The effect of BNF on the proliferation of human esophageal carcinoma 
cells (WHCO1 and WHCO6) after 24 hours. At least three independent studies were conducted 
in triplicates each time. Cells were plated at a density of 5000 cells/well in a 96 well plate and incubated 
with increasing concentrations of BNF for 24 hours. BP and ANF were used as negative controls and 
3MC as a positive control. Cell proliferation was measured by the MTT assay and the percentage of 
viable cells relative to the control (cells treated with DMSO only) was calculated for each concentration. 
Results are presented as the means ± SD from three independent experiments. Statistical differences were 
determined with the one-way ANOVA followed by Tukey’s post comparison test. P<0.05 was considered 
significant.  
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Figure 3.3: The effect of BNF on the proliferation of human esophageal carcinoma 
cells (WHCO1 and WHCO6) after 48 and 72 hours. At least three independent studies were 
conducted in triplicates each time. Cells were plated at a density of 5000 cells/well in a 96 well plate and 
incubated with increasing concentrations of BNF for 48 and 72 hours. BP and ANF were used as negative 
controls and 3MC as a positive control. Cell proliferation was measured by the MTT assay and the 
percentage of viable cells relative to the control (cells treated with DMSO only) was calculated for each 
concentration. Results are presented as the means ± SD from three independent experiments. Statistical 
differences were determined with the one-way ANOVA followed by Tukey’s post comparison test. 
P<0.05 was considered significant.  
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3.3.2. The median inhibition concentration (IC50) values of BNF in 
WHCO1 and WHCO6 cells. 
For a compound to be considered as anticancerous it must display the desired 
level of inhibitory activity against the target cell type. Activity is expressed as 
the median inhibition concentration (IC50) which is the concentration at which 
a given test compound inhibits cell proliferation by 50%. The 50% 
proliferation was calculated relative to control cells (0.2% DMSO treated cells) 
designated as 100% viable cells. Figure 3.4 shows the effects of varying BNF 
concentrations on the two cell lines. For the WHCO1, to reach 50% toxicity, a 
concentration of 25 uM was required while for the WHCO6, 50% toxicity was 
reached with the use of 10 uM BNF.  
 
BNF resulted in IC50 after treating WHCO1 cells with 25µM BNF and 
incubating them for 24 hours while 10µM BNF resulted in IC50 in the WHCO6 
after incubating them for 48 hours period.  
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 Figure 3.4: The median inhibition concentration (IC50) of BNF in WHCO1 
and WHCO6 cells. IC50 is a concentration at which 50% of cell growth is inhibited. The red 
dotted line shows 50% cell growth inhibition. Results represent means ± SD of at least 3 
different experiments conducted in triplicates each time. P<0.05 is considered significant 
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3.4. Discussion and Conclusion 
Flavonoids are polyphenolic compounds occurring in plants. They have been 
found in dietary components such as fruits, vegetables, and tea (Barnes et al, 
2001; Liu, 2003). Besides their role in plants, these compounds have shown to 
reduce the risk of cancer development and other major chronic diseases 
(Marchand et al, 2000). 
 
ß-Naphthoflavone (BNF) is a synthetic derivative of a naturally occurring 
flavonoid. The antitumor effects of BNF have been investigated only recently. 
This flavonoid has been shown to possess antiproliferative effects in breast 
cancer cells (MCF7) (Cárdenas et al, 2006). However, there are few reports 
documenting the anticancerous activities of BNF in other cancer cell types. 
Therefore, in the current study the antitumor activities of BNF in human 
esophageal cancer cells, WHCO1 and WHCO6 cells were further explored. 
 
BNF exerted significant antiproliferative effects against both cancer cell lines. 
The antiproliferative effects were expressed as the median inhibition 
concentration (IC ) values. Based on the IC50 50 values, compounds are usually 
classified as either highly active (IC < 10µM) or moderately active (IC50 50~10-
20µM) (Cárdenas et al, 2006). The magnitude of the antiproliferative effects of 
BNF were different in the two cell lines, WHCO6 responded very well to low 
BNF concentrations while WHCO1 cells needed a higher concentration of 
BNF. Interestingly, BNF effect diminished over time in WHCO1 cells while in 
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WHCO6 cells the effect increased. BNF caused moderate antiproliferation in 
WHCO6 (IC  =10µM) but weak effect in WHCO1 cells (IC50 50 =25µM).The 
reason for the differences in response to BNF in both WHCO1 and WHCO6 
could be due to the contribution of metabolizing gene polymorphisms in the 
two cell lines. These results therefore support the observation that cancerous 
tumors usually contain cell subpopulations with different biological properties 
and suggest a differential selective action in different cell types.  
 
The effect of BNF on proliferation was compared to some of the well studied 
compounds, BP, 3MC and ANF. BP, a polyaromatic hydrocarbon (PAH) 
which is commonly present in tobacco smoke has been implicated in the 
induction of cell proliferation (Jeffy et al, 1999, Culp et al, 2000; Jeffy et al, 
2002). To exert its adverse health effects, BP requires metabolic activation to a 
biologically reactive intermediate. The cell proliferation effect of BP has been 
studied in several cell lines, thus this hydrocarbon together with ANF, one of 
the most common CYP1 inhibitors (Gasiewicz and Rucci, 1991; Gasiewicz et 
al, 1996) were used as negative controls in this study. The data clearly showed 
that both BP and ANF did not have detectable antiproliferative effects in both 
WHCO1 and WHCO6 but instead, treatment of cell lines with these 
compounds resulted in significantly increasing cell proliferation even at low 
concentrations. These results are in agreement with previous findings that have 
shown BP to enhance proliferation of human breast cancer cells and lung 
cancer cells (Tsai et al, 2004; Kometani et al, 2009).  
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3MC which is one of the well known CYP1 classical inducers was shown to 
have antiproliferative effects in both WHCO1 and WHCO6 cell lines. This 
type of behavior was also reported in previous studies whereby 3MC displayed 
antiproliferative effects in human keratinocyte cell line NCTC 2544 (Gelardi et 
al, 2001), rat calvarial osteoblast-like cells and mouse calvarial clonal 
preosteoblastic cells (MC3T3-E1) (Naruse et al, 2002).  
 
The results also showed that BNF was associated with significant 
antiproliferative effects on esophageal cancer cells and thus it would be 
suggested that esophageal cancer cells may be responsive to the treatment with 
BNF. However, further investigations in this direction are required. 
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CHAPTER 4: The effects of BNF on the 
expression of CYP1A1, CYP1A2, CYP1B1 and 
AHR in the two esophageal cancer cell lines, 
WHCO1 and WHCO6 
 
4.1. Introduction 
 
The human cytochrome P450 (CYP) 1 gene family is one of the main CYP 
families involved in the metabolism of a wide range of xenobiotics (Gonzalez 
and Gelboin, 1994; Shimada et al, 1996; 1997; Crespi et al, 1997) and consists 
of three known enzymes, CYP1A1, CYP1A2 and CYP1B1. The inducible 
expression of the CYP1 family is regulated via the aryl hydrocarbon receptor 
(AHR) complex (Hankinson, 1995; Schmidt and Bradfield, 1996). In its 
inactive form, the AHR is located in the cytosol where it is bound to a dimmer 
of heat shock proteins (HSP90), one molecule of p23 and one molecule of the 
AHR interacting protein (AIP) (Hollingshead et al, 2004; Bock and Kohle, 
2006). Upon ligand binding the AHR dissociates from the proteins and forms a 
ligand-AHR complex. This complex is translocated to the nucleus and forms a 
heterodimer with the aryl nuclear translocator (ARNT) (Fujii-Kuriyama and 
Mimura, 2005). This heterodimer binds to the xenobiotic response element and 
activates the transcription of numerous genes, including CYP1A1, CYP1A2, 
and CYP1B1 (Hankinson, 1995; Mimura and Fujii-Kuriyama, 2003). 
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This chapter describes the experiments that were carried out using Western blot 
analysis to investigate the effect of BNF on the expression of individual 
members of the CYP1 gene family in WHCO1 and WHCO6 esophageal cancer 
derived cell lines. The expression of these forms of CYPs was compared to that 
of the AHR. 
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4.2. Materials and Methods 
4.2.1. Cell Culture and Treatment 
WHCO1 and WHCO6 cells were maintained by following the protocol 
described in chapter 2 (Section 2.2.1). At 60-80% confluence the cells were 
rinsed with 1X phosphate buffer saline (PBS), (136.8 mM NaCl, 2.68 mM KCl, 
10.1 mM Na2HPO4·12H2O, 1.76 mM KH2PO4 pH 7.2), trypsinized with 
trypsin/ EDTA (0.01% trypsin, 0.004% EDTA) and seeded into10 cm tissue 
culture dishes (Falcon). After 24 hours the cells were rinsed with 1X PBS and 
treated with BNF(WHCO1 cells treated with 25µM BNF for 24 hours and 
WHCO6 cells treated with 10µM BNF for 48 hours) and incubated at 37ºC, 
95% humidity and 5% CO2. Control cells were treated with 0.2% DMSO. 
Whole cell extractions of the treated and control cells were performed after the 
incubation period of each cell line.  
 
4.2.2. Whole Cell protein Extraction 
Cells were rinsed three times with ice-cold PBS and scraped off the dish in a 
final volume of 1ml PBS and transferred into a sterile eppendorf tube. The cells 
were centrifuged at 1145 x g for 2 minutes using the bench top mini centrifuge. 
The supernatant was discarded and the pellet resuspended in 100µl Laemmli 
sample buffer (Appendix 7.1). The samples were boiled for 5 minutes followed 
by centrifugation at 10 000g for 10 minutes at 4ºC. The samples were then 
stored at -70°C. 
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4.2.3. Protein Estimation 
The protein concentrations of the cell extracts were determined using the 
method proposed by Bramhall et al, 1969. This method is described below. A 
15cm filter paper (Whatman) was rinsed in distilled water for 20 minutes. This 
was followed by rinsing in 95% ethanol for 5 minutes, 99% ethanol for 5 
minutes, acetone for 5 minutes, consecutively, in order to dehydrate the filter 
paper. The filter paper was then left under a fume hood to dry. Bovine serum 
albumin (BSA) was dissolved in Laemmli sample buffer (Appendix 7.1) to 
make a final concentration of 2µg/µl. A range of protein standards with a final 
concentration of between 1 and 20µg BSA were prepared and loaded onto the 
dry filter paper. Five (5) µl of each protein sample was also loaded onto the 
filter paper. The filter paper was left under the fume hood to dry. 
 
The BSA standards and the protein samples were fixed within the filter paper 
by rinsing the filter paper with 7.5% tichloro-acetic acid (TCA) (Appendix 7.2) 
for 40 minutes and stained for 45 minutes with 0.25% coomassie blue stain 
solution (Appendix 7.2). The filter paper was destained in destaining solution 
(Appendix 7.2) until only the stained protein spots and BSA standards sports 
remained. The filter paper was left to dry and the stained spots were 
individually cut and placed in 5ml elution solution (Appendix 7.2) overnight in 
the dark. The absorbance of each sample was measured at 596nm. The BSA 
standards absorbance values were used to construct a standard curve. The 
concentration of each protein sample was calculated from the standard curve. 
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 4.2.4. SDS-PAGE 
The SDS-PAGE method used was adapted from Laemmli, 1970. A 10% 
separating gel (Appendix 7.3) and 5% stacking gel (Appendix 7.3) were 
prepared. Each sample was loaded to the gel at the required volume to obtain 
35µg of protein for the detection of CYP1A1, 25µg for the detection CYP1A2, 
15µg for the detection of CYP1B1 and 10µg for the detection of AHR. Protein 
molecular weight marker (Fermentas) was also loaded. The gel was 
electrophoresed at a constant current of 25 milli-Amps (mA) in running buffer 
(Appendix 7.3). 
 
4.2.5. Western Blotting 
For the detection of 56kDa CYP1A1, CYP1A2, and CYP1B1 as well as 
122kDa AHR proteins, the proteins were electrically transferred from the gel 
onto the nitrocellulose membranes, in transfer buffer (Appendix 7.4) for 1 hour 
at a constant current of 400mA using the Biorad mini trans-blot system. The 
membranes were rinsed 3 times with PBS. To block non-specific proteins, the 
membranes were incubated for 1 hour in 5% non-fat milk powder in Tris 
buffered saline (TBS) or 5% BSA in Tris buffered saline containing 0.1% 
Tween-20(TBST). The membranes were rinsed 6 times with PBS or TBST and 
incubated overnight at 4ºC with rabbit anti-CYP1A1 antibody (1:1000, 
SANTA CRUZ), rabbit anti-CYP1A2 (1:1500, SANTA CRUZ), rabbit anti-
CYP1B1 (1:1000, SANTA CRUZ) or rabbit anti AHR antibody (1:800, 
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SANTA CRUZ) in 1% BSA. After 6 X 5 minutes rinsing in PBS or TBST the 
membranes were incubated with 1:5000 horseradish peroxidase conjugate 
(HRP) goat anti-rabbit antibody (Sigma) for an hour in 1% BSA or 5% non-fat 
milk powder at room temperature in the dark. The membranes were then rinsed 
for a further 30 minutes in PBS or TBST at 5-minute intervals. The super 
signal west pico chemiluminescent substrate kit (Pierce) (Appendix 7.4) was 
used for the detection of of the proteins. The membranes were then exposed to 
the hyperfilm for 10 minutes. The film was developed for 5 minutes in the 
developer (Appendix 7.4), rinsed with water and placed in fixer (Appendix 7.4) 
for 5 minutes and finally rinsed with water. 
 
4.2.6. Densitometry 
Densitometric methods are used to measure the relative quantities of proteins 
on the blot compared to the control proteins. LabWorksTM Image Acquisition 
and analysis Software (LabWorks version 4.5) was used to quantitatively 
determine the concentration level of CYP1A1, CYP1A2, CYP1B1 and AHR. 
 
4.2.7. Statistical Analysis 
The results were expressed as means ±standard deviations (S.D) for at least 
three independent experiments. Significant differences between the control 
cells and BNF treated cells were determined using the T-test (Excel 2003) 
(Appendix 8). A probability level of p<0.05 was considered significant. 
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4.3. Results 
 
4.3.1. SDS-PAGE for protein estimation 
 
To compare a change in expression between treated and non- treated samples 
using Western blotting the same concentration of both samples was used. Each 
sample was loaded to the gel at the required volume to obtain 15µg of protein. 
Figure 4.1 shows SDS-PAGE of samples extracted from WHCO1 and WHCO6 
cell lines. The uniform band intensities obtained for background protein for all 
samples analyzed by SDS-PAGE (Figure 4.1), is confirmation that similar 
concentrations of cell lysate were loaded in each well. 
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Figure 4.1 SDS-PAGE of samples extracted from WHCO1 and WHCO6 cell 
lines. Whole cell protein extraction was used and the total protein was estimated as explained 
in materials and methods. 15µg of each sample was loaded in each lane. Lanes- M: Marker, 
Lane 1: WHCO1 control, Lane 2: WHCO1 BNF treated, Lane 3: WHCO6 control, Lane 4: 
WHCO6 BNF treated. 
 
4.3.2. The effect of BNF on CYP1A1, CYP1A2, CYP1B1 and AHR protein 
expression 
To examine the effect of BNF on the expression of CYP1A1, CYP1A2, 
CYP1B1 and AHR, both WHCO1 and WHCO6 cells were treated with their 
respective BNF IC50 concentrations whereby the WHCO1 cells were treated 
with 25µM BNF for 24 hours and WHCO6 cells were treated with 10µM BNF 
for 48hours. The expression of these proteins was measured using Western blot 
analysis. Fold increases or decreases in protein expression was determined by 
130 kDa 
35 kDa 
25 kDa 
100 kDa 
70 kDa 
55 kDa 
40 kDa 
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comparing protein levels of CYP1A1, CYP1A2, CYP1B1 and AHR in BNF 
treated cells to protein levels of each respective gene in control cells by using 
the densitometric band intensities of Western blots. 
 
4.3.2.1. The effect of BNF on CYP1A1 protein expression 
 
The CYP1A1 protein was constitutively expressed in both WHCO1 and 
WHCO6 cell lines. Treatment of these cells with BNF resulted in an increase in 
CYP1A1 protein expression that was significantly different (Appendix 8) from 
the controls. WHCO1 cells treated with BNF displayed a 1.3 fold increase in 
CYP1A1 protein expression compared to control cells (P=0.02) (Figure 4.2) 
while WHCO6 cells treated with BNF displayed a 1.1 fold increase in CYP1A1 
protein expression compared to control cells (P=0.01). 
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Figure 4.2 The effect of BNF on the expression of CYP1A1 protein in 
WHCO1 and WHCO6 cells. Representative Western blots are shown in this figure. 
WHCO1 and WHCO6 cells were exposed to 25µM BNF for 24 hours and 10µM BNF for 48 
hours, respectively, while control cells were treated with 0.2% DMSO. 35µg of the whole cell 
protein extract of each sample was loaded in each lane. The transferred proteins were probed 
with rabbit anti-CYP1A1 antibody followed by (HRP) goat anti-rabbit antibody. The 
densitometric band intensities of Western blots are expressed as fold change relative to the 
control. Statistical differences were determined by using the T-test whereby P< 0.05 was 
considered significant. 
 
4.3.2.2. The effect of BNF on CYP1A2 protein expression 
 
Similar to the CYP1A1, CYP1A2 protein was also discovered to be 
constitutively expressed in WHCO1 and WHCO6 cells. The treatment of 
these cells with BNF displayed an increase in CYP1A2 protein expression as 
shown on figure 4.3. The change in CYP1A2 protein expression was 
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significantly increased to approximately 1.4 fold over control cells in both cell 
lines (P=0.01 in WHCO1, P=0.05 in WHCO6).  
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Figure 4.3 The effect of BNF on the expression of CYP1A2 protein in 
WHCO1 and WHCO6 cells. Representative Western blots are shown in this figure. 
WHCO1 and WHCO6 cells were exposed to 25µM BNF for 24 hours and 10µM BNF for 48 
hours, respectively, while control cells were treated with 0.2% DMSO. 25µg of the whole cell 
protein extract of each sample was loaded in each lane. The transferred proteins were probed 
with rabbit anti-CYP1A2 antibody followed by (HRP) goat anti-rabbit antibody. The 
densitometric band intensities of Western blots are expressed as fold change relative to the 
control. Statistical differences were determined by using the T-test whereby P< 0.05 was 
considered significant.  
4.3.2.3. The effect of BNF on CYP1B1 protein expression 
 
Figure 4.4 shows the effect of BNF on the expression of CYP1B1 protein. The 
CYP1B1 constitutive expression was very low in both cell lines, however, 
significant inductions in CYP1B1 protein expression were observed after BNF 
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treatment. WHCO1 cells treated with BNF showed a 2.4 fold increase in 
CYP1B1 protein expression compared to control cells (P=0.003) (Figure 4.4) 
while WHCO6 cells treated with BNF displayed a 1.7 fold increase in CYP1B1 
protein expression compared to control cells (P=0.05) (Figure 4.4). 
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Figure 4.4 The effect of BNF on the expression of CYP1B1 protein in 
WHCO1 and WHCO6 cells. Representative Western blots are shown in this figure. 
WHCO1 and WHCO6 cells were exposed to 25µM BNF for 24 hours and 10µM BNF for 48 
hours, respectively, while control cells were treated with 0.2% DMSO. 15µg of the whole cell 
protein extract of each sample was loaded in each lane. The transferred proteins were probed 
with rabbit anti-CYP1B1 antibody followed by (HRP) goat anti-rabbit antibody. The 
densitometric band intensities of Western blots are expressed as fold change relative to the 
control. Statistical differences were determined by using the T-test whereby P< 0.05 was 
considered significant.  
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4.3.2.4. The effect of BNF on AHR protein expression 
 
Treatment of WHCO1 and WHCO6 cells with BNF caused a down regulation 
in AHR protein expression that was significantly different (Appendix 8) from 
the controls. WHCO1 cells treated with BNF caused a 1.3 fold decrease in 
AHR protein expression compared to the control cells (P=0.003) (Figure 4.5). 
With regard to the WHCO6 cells, BNF caused a 4.5 fold decrease in AHR 
protein expression compared to the control cells (P=0.004) (Figure 4.5). 
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Figure 4.5: The effect of BNF on the expression of AHR protein in WHCO1 
and WHCO6 cells. Representative Western blots are shown in this figure. WHCO1 and 
WHCO6 cells were exposed to 25µM BNF for 24 hours and 10µM BNF for 48 hours, 
respectively, while control cells were treated with 0.2% DMSO. 10µg of the whole cell protein 
extract of each sample was loaded in each lane. The transferred proteins were probed with 
rabbit anti-AHR antibody followed by (HRP) goat anti-rabbit antibody. The densitometric band 
intensities of Western blots are expressed as fold change relative to the control. Statistical 
differences were determined by using the T-test whereby P< 0.05 was considered significant. 
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4.3.3. BNF induces the expression of CYP1B1 protein to significantly 
higher levels than CYP1A1 and CYP1A2 proteins in WHCO1 and 
WHCO6 cells 
 
To compare the relationship amongst CYP1A1, CYP1A2 and CYP1B1 protein 
expression in response to BNF treatment in WHCO1 and WHCO6 cells, the 
ratios of CYP1B1 to CYP1A1 fold changes (CYP1B1 fold change/CYP1A1 
fold change), CYP1B1 to CYP1A2 fold changes (CYP1B1 fold 
change/CYP1A2 fold change), and CYP1A2 to CYP1A1 fold changes 
(CYP1A2 fold change/CYP1A1 fold change) were calculated for each cell line 
(Table 4.1). Ratios that are greater than one, for example in terms of the 
CYP1B1 to CYP1A1 fold change, would mean that the expression of CYP1B1 
was induced to a higher level than the expression of CYP1A1 protein (Table 
4.1). Similar conclusions were made for the other protein ratio changes.   
 
Table 4.1: Comparison of CYP1A1, CYP1A2 and CYP1B1 expression in 
BNF treated cells.  
Dose 
(µM)) 
Time 
(h) Cell line CYP1B1/1A1 ratio CYP1B1/1A2 ratio CYP1A2/1A1 ratio 
WHCO1 25 24 2.2 1.7 1.1 
WHCO6 10 48 1.6 1.2 1.3 
 
Ratios that are greater than one (1) show a higher level of induction 
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4.4. Discussion  
4.4.1. BNF induces the expression of CYP1 enzymes 
Flavonoids are a large class of phenolic compounds present in fruits, vegetables 
and other plant foods and have been shown to reduce the risk of cancer and 
other major chronic diseases. They show their effects by either delaying or 
reversing the process of carcinogenesis. At the first entry site, procarcinogens 
are metabolized in phase I reactions catalyzed by CYP enzymes (Conney, 
2003; Guengerich, 2004; Caro and Cederbaum, 2004; Coon, 2005; Kim and 
Guengerich, 2005) and are then conjugated with water soluble endogenous 
metabolites by phase II enzymes, thus producing hydrophilic products that can 
be easily excreted (Burchell, 2003; Kuuranne et al, 2003). However, phase I 
products are not always conjugated by phase II enzymes since the phase I 
products are often highly reactive metabolites capable of causing toxicity 
(Guengerich, 2000; Schwarz et al, 2001). 
 
Flavonoids have been shown to interact with CYP enzymes in at least three 
ways: they induce the biosynthesis of several CYPs, they modulate (inhibit or 
stimulate) the activities of CYP enzymes and flavonoids are also metabolized 
by several CYPs (Hodek et al, 2002). Some of the beneficial properties of 
flavonoids include inhibition of CYPs involved in carcinogen activation and 
scavenging of reactive radicals formed from carcinogens by CYP-mediated 
reactions (Chan et al, 1998; Zhai et al, 1998; Doostdar et al, 2000; Henderson 
64 
 
et al, 2000). Flavonoids can also prevent the process of carcinogenesis by 
induction of phase II enzymes as well. 
 
In the current study, the inducible expression of the enzymes (CYP1A1, 
CYP1A2 and CYP1B1) in response to treatment of esophageal cancer cells, 
WHCO1 and WHCO6 by the synthetic flavonoid BNF was investigated. An 
induction of CYP1A1, CYP1A2 and CYP1B1 by BNF is reported in this study. 
This flavonoid was shown to induce CYP1A1 by 1, 3 and 1, 1 fold in WHCO1 
and WHCO6 cells, respectively. It was also shown to induce CYP1A2 by 1, 4 
fold in both cell lines. In addition, this flavonoid also induced CYP1B1 by 2.4 
and 1, 7-fold induction in WHCO1 and WHCO6 cells, respectively. 
 
Although CYP enzymes generally convert xenobiotics to less toxic 
compounds, the reactions frequently involve the formation of reactive 
intermediates capable of causing toxicity. Elevation of activities of CYP1 
family of enzymes (CYP1A1, CYP1A2 and CYP1B1) is highly unwanted 
since these enzymes are responsible for activation of carcinogens such as BP, 
7, 12-dimethylbenz (a) anthracene (DMBA), Aflatoxin B1 and meat derived 
heterocyclic aromatic amines (Omiecinski et al, 1999). CYP1 induction can 
also cause an imbalance between phase I and phase II reactions, for example 
when CYP1 enzymes are more active than phase II enzymes, this can cause an 
accumulation of phase I products capable of causing toxicity (Guengerich, 
2000; Schwarz et al, 2001). CYP1 enzymes have broad substrate specificities 
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therefore induction of these enzymes may result in alteration of pharmaceutical 
drugs thus causing an overdose or loss of their therapeutic effect (Tang and 
Stearns, 2001; Rochat et al, 2001; Mcfadyen et al, 2001; Bournique and 
Lemarie, 2002).  
 
The induction of CYP1 enzymes is recognized as a factor in determining the 
risk of the development of cancer. Increased expression of CYP1A1 in the 
lungs increases the risk of lung cancer (McLemore et al, 1990; Guengerich, 
1988) as well as colorectal cancer (Sivaraman et al, 1994). CYP1A2 also has a 
role in the development of cancers associated with tobacco smoking. 
Differential expression of the CYP1 enzymes was observed in WHCO1 and 
WHCO6 cells, with CYP1B1 induction being the highest compared to the other 
enzymes after BNF exposure. CYP1A1 was the second highly induced enzyme 
while CYP1A2 was induced the least after BNF exposure. These results are in 
agreement with previous results that showed CYP1B1 enzyme to be more 
active than CYP1A enzymes in metabolizing several compounds to reactive 
intermediates (Shimada et al, 1996; Li et al, 1998; Yengi et al, 2003; Wen and 
Walle, 2005; Walle et al, 2006). CYP1B1 induction can thus be used as a target 
in cancer therapy and prevention, especially since this enzyme has been shown 
to be up-regulated in a wide variety of cancers (Murray et al, 1997; Ko et al, 
2001; Murray et al, 2001; McFadyen et al, 2001; Tanaka et al, 2002; Chang et 
al, 2003; Carnell et al, 2004; Wen and Walle, 2005; Walle et al, 2006). 
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When comparing the ratio of protein level in both WHCO1 and WHCO6 cells, 
the induction of the CYP1 enzymes was higher in WHCO1 than in WHCO6 
cells. These results therefore suggest that the ability of BNF in increasing the 
CYP1 protein level differs with different cell lines. One reason for the variation 
in the ratio of protein level in both cell lines could be due to CYP1 
polymorphisms, especially since these cell lines originate from different 
individuals. Genetic polymorphisms of CYP1A1 enzymes have been linked 
with a higher risk for the development of a wide range of cancers (San Jose et 
al, 2010; Jin et al, 2011). Several studies have also reported the association of 
CYP1A2 with an increased risk of a wide range of cancers (Landi et al, 1999; 
Williams et al, 2000). In addition to the above studies, the up-regulation of 
CYP1B1 has also been shown to be associated with various cancer types 
(Watanabe, 2000;Ko et al, 2001; Goodman et al, 2001; Tanaka et al, 2002 ; 
Gattás et al, 2006;   Varela-Lema, 2008; Ozbek et al, 2010). The results 
presented in this study provide more evidence about the potential of the CYP1 
enzymes as targets in cancer therapy and prevention. 
 
4.4.2. BNF down-regulates the expression of AHR 
The AHR is a ligand activated basic helix-loop-helix (bHLH) protein that 
belongs to the Per-Arnt-Sim (PAS) family of transcription factors (Schimidt 
and Bradfied, 1996). In this study, BNF, which is one of the most potent AHR 
ligands, was used to investigate the effect it had on the AHR protein expression 
in esophageal cancer cells, WHCO1 and WHCO6 cells. The results showed a 
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1.3 and 4.5 fold down-regulation of AHR in WHCO1 and WHCO6, 
respectively, in the presence of the ligand BNF. These results are in agreement 
with previous studies that showed a down-regulation of AHR protein upon 
ligand exposure both in vivo and in vitro (Prokipcak and Okey, 1991; Swanson 
and Perdew, 1993; Giannone et al, 1995; Pollenz, 1996; Giannone et al, 1998; 
Pollenz et al, 1998; Roman et al, 1998; Davarinos and Pollenz, 1999; Ma and 
Baldwin, 2000; Wormke et al, 2000; Santiago-Josefat et al, 2001). 
 
Previous studies have also shown that the mechanism of AHR 
downregulation upon ligand binding involves nuclear export of the AHR, 
ubiquination followed by protein degradation by the 26S proteasome (Pollenz, 
1996; Pollenz et al, 1998; Giannone et al, 1998; Pollenz and Barbadour, 
2000; Ma and Baldwin, 2000; Pollenz, 2002), which thus cause the reduction 
of the protein available. This does not occur in control cells, since in control 
cells, the AHR protein remains inactive and localized in the cytosol where it 
is not at risk of being ubiquinated and degraded via the 26S proteasome. 
 
Another reason for the AHR downregulation in BNF treated cells compared 
to control cells could involve the AHRR, where the liganded AHR in a 
heterodimer with ARNT leads to the activation of the AHRR protein, while 
the up-regulated AHRR, in turn, reduces the expression of AHR (Mimura et 
al, 1999). 
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4.5. Conclusion  
In general, the induction of CYP1 enzymes is highly unwanted, since these 
enzymes have been shown to convert xenobiotics to reactive and carcinogenic 
metabolites. According to the results obtained, BNF was shown to be a CYP1 
inducing compound. BNF may therefore be considered as harmful since 
exposure to it could lead to an increase in the rate of metabolism of other 
carcinogenic compounds. The results also showed the differential induction of 
the CYP1 protein levels after BNF exposure, which suggests the presence of 
polymorphisms of these enzymes. Together, these results, implicate CYP1 
enzymes, especially the CYP1B1, as potential therapeutic targets for cancer 
prevention. 
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CHAPTER 5: General discussion 
                        
In South Africa, esophageal cancer is the most prevalent cause of cancer 
related deaths in black males (Sitas, 1992). Although different factors can 
play a role in the development of this disease, reports have shown that 
alcohol consumption and tobacco smoking are the main risk factors for 
esophageal cancer (Montesano et al, 1996, Castellsaqũe et al, 1999). The 
development of esophageal cancer is asymptomatic, thus resulting in late 
diagnosis and poor prognosis. Success in treatment has been limited in 
terms of esophageal cancer management; therefore, surgery is still the 
major intervention when the disease is detected relatively early. Therefore, 
early detection and search for potential anticancer compounds are 
important in the control of esophageal cancer.  
 
Flavonoids, a large class of phenolic compounds present in plants, have 
been shown to influence a wide range of biological functions, including 
the inhibition of tumor growth and the prevention of cancer (Harborne et 
al, 1999). Various natural flavonoids were also shown previously to have 
antiproliferative activities against several human cancer cell lines (HeLa, 
MCF7, SK-Mel-28 and KB) (Cárdenas et al, 2006). Considering the 
antiproliferative activities of some flavonoids on certain cancer cells and 
due to a lack of such information on esophageal cancer cells, in the current 
study the antiproliferative activity of a synthetic flavonoid, ß-
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Naphthofglavone (BNF), on esophageal cancer cells WHCO1 and 
WHCO6 was evaluated. BNF showed a moderate activity in WHCO6 
cells (IC  ~ 10µM) and a weak activity in WHCO1 cells (IC50 50 ~ 
25µM).Viewed generally, the results show that the growth inhibitory 
activity of BNF against the two cell lines is not always the same, thus 
indicating differences in the sensitivity of cancer cells to BNF. The 
number and position of hydroxyl groups and double bonds are the 
determining factors for flavonoid antiproliferative activities (Kozikowsk et 
al, 2003). Flavonoids with 4-6 hydroxyl groups have been shown to have 
strong antiproliferative activities, whereas those with more or fewer 
hydroxyl groups show low or no antiproliferative activities (Rice-Evans et 
al, 1995; Rice-Evans et al, 1996; Rice-Evans, 2001). One of the reasons 
that BNF did not show the greatest effect on the proliferation of the 
WHCO1 and WHCO6 cells could be due to its lack of hydroxyl groups. 
However, the current results still demonstrate that even though the 
antiproliferative activity of BNF was not outstanding, esophageal cancer 
cells may still be responsive to the treatment with this flavonoid. 
 
Flavonoids contribute to the prevention of cancer through several 
mechanisms. They may act in different stages of the development of 
cancer by scavenging free radicals, thus protecting the DNA from 
oxidative damage (Ferguson, 2001). Flavonoids have been shown to 
inactivate carcinogens by inhibiting the expression of mutagenic genes. 
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They have also been shown to inactivate enzymes responsible for the 
activation of procarcinogens and activate the ones responsible for the 
detoxification of xenobiotics (Bravo et al, 1998). 
 
Among the proteins that interact with flavonoids, CYP monooxygenase 
metabolizing xenobiotics and endogenous substrates play a major role 
(Hodek et al, 2002). The CYP inhibitory capacity of flavonoids has been 
widely studied due to their potential use as agents blocking carcinogenesis 
(Chan et al, 1998; Zhai et al, 1998; Doostdar et al, 2000; Henderson et al, 
2000). Certain flavonoids alter the expression of CYP1 enzymes thus 
inhibiting the activation of procarcinogens to carcinogens and ultimately 
to a reduction of DNA adduct formation. Reports have shown that 
flavonoids possessing hydroxyl groups are usually associated with an 
inhibition of CYP enzyme activity, whereas those lacking hydroxyl groups 
often stimulate CYP enzyme activity. BNF, which does not possess any 
hydroxyl groups, and was found to significantly induce the expression of 
CYP1A1, CYP1A2 and CYP1B1 in both WHCO1 and WHCO6 cells. 
 
CYP1A1 is one of the key enzymes in the activation of procarcinogens to 
carcinogens (Guengerich, 1992; Shimada et al, 1992; Guengerich, 1999; 
Minsavage et al, 2004; Schwartz et al, 2007). This enzyme was induced 
by 1.3 and 1.1 fold in WHCO1 and WHCO6 cells, respectively, upon 
exposure to BNF. The induction of CYP1A1 by BNF may result in an 
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increase in the capacity of CYP1A1 mediated carcinogen activation thus 
leading to a development of neoplastic diseases. On the other hand, the 
induction of this enzyme may mean that when exposed to potential 
carcinogens these carcinogens will be activated and thus be detoxified by 
phase II enzymes and readily eliminated from the body (Burchell, 2003; 
Kuuranne et al; 2003). 
 
CYP1A2 enzymes are known for their oxidative metabolism of a wide 
range of therapeutic drugs (Yamazaki et al, 2001; Daniel et al, 2002; 
Llibre et al, 2002). BNF induced this enzyme by 1.4 fold in both cell lines. 
Since CYP1A2 metabolizes therapeutic drugs, the simultaneous 
administration of BNF and therapeutic drugs may cause an altered 
pharmacokinetics of the drugs thus resulting in either overdose or loss of 
their therapeutic effect (Tang and Stearns, 2001). Some people are slow 
drug metabolizers, therefore, the simultaneous administration of their 
therapeutic drugs and BNF may be beneficial in the activation and 
improvement of drug transportation in such people. 
 
CYP1B1 is well known for the steroid metabolism to the carcinogenic 
metabolite 4-hydroxyesstradiol (4-OHE2) (Badawi et al, 2001; Cavalieri 
and Rogan, 2004). This metabolite has been implicated in causing several 
types of cancer, including breast cancer (Mckay et al, 1995; Liehr and 
Ricci, 1996; Murray et al, 1997). BNF induced CYP1B1 by 2.4 and 1.7 in 
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WHCO1 and WHCO6 cells, respectively. Induction of CYP1B1 is a risk 
factor for breast cancer because it is a major enzyme for the carcinogenic 
estrogen metabolism. 
 
A differential expression of the CYP1 proteins was observed in both 
WHCO1 and WHCO6 cell lines. One reason for the variation in the ratio 
of protein level in both cell lines could be due to CYP1 polymorphisms 
that may contribute to interindividual susceptibility to environmental 
carcinogens. Genetic polymorphisms of CYP1A1 enzymes have been 
linked with a higher risk for the development of a wide range of cancers. 
Several studies have also reported the association of CYP1A2 with an 
increased risk of a wide range of cancers (Landi et al, 1999; Williams et 
al, 2000). CYP1B1 was highly expressed compared to the CYP1A 
proteins. This could be because CYP1B1 has been shown to be expressed 
at high frequencies in various human cancers, including breast, colon, 
lung, esophagus, skin, lymph node, brain, and testicles but not in normal 
tissues (Murray et al, 1997; Watanabe, 2000; Ko et al, 2001; Tanaka et al, 
2002; Gattás et al, 2006; Varela-Lema, 2008). Together, these findings 
implicate CYP1 enzymes, especially the CYP1B1, as potential therapeutic 
targets for esophageal cancer prevention. 
 
Aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor 
which regulates CYP1 enzymes. Inhibiting the CYP1 family of enzymes 
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through blocking the AHR plays a critical role in the cancer 
chemopreventive properties of flavonoids. For instance, quercetin, one of 
the well known naturally occurring flavonoids, binds as an antagonist to 
AHR and consequently inhibits benzo(a)pyrene (BP) induced CYP1A1 
mRNA transcription and protein expression and thus resulting in 
decreased BP-DNA adduct formation (Kang et al, 1999). In the present 
study, BNF did not show an induction but a down-regulation of the AHR 
in both cell lines. BNF down-regulated AHR by 1.3 and 4.5 fold in 
WHCO1 and WHCO6, respectively. The mechanism of AHR down-
regulation upon ligand binding has been reported to involve nuclear export 
of the AHR, ubiquination, followed by protein degradation by the 26S 
proteasome (Pahl and Baeuerle, 1996; Tanaka, 1998; Davarinos and 
Pollenz, 1999; Ciechanover et al, 2000; Kornitzer and Ciechanover, 2000; 
Pollenz, 2002).  
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Conclusion and Future studies 
Summarizing the above results, the agonist function of BNF seems not to 
be in line with its anticancer properties. However, BNF induction of the 
CYP1 enzymes may facilitate the removal of other compounds that are 
already active in the body. This flavonoid may prevent the process of 
carcinogenesis by other mechanisms such as the induction of both the 
phase I and phase II enzymes, thus the reactive intermediates that are 
formed as a result of metabolism of other compounds are removed from 
the body in a coordinated way. In future, it will be important to evaluate 
the effects of BNF on phase II enzymes such as the glutathione 
transferases, UDP glucuronosyltrallsferases and Nacetyl transferases, in 
order to find out how this flavonoid affects the detoxification pathway 
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APPENDICES 
                                     
Appendix 1 
 
1.1. MTT cell viability assay 
1.1.1. MTT labeling reagent 
MTT (3-[4, 5-dimethyl thiazol-2-yl]-2, 5-diphenyl tetrazolium bromide) 
Dissolved in phosphate buffred saline to make a final concentration of 5mg/ml 
 
1.1.2. MTT Solubilization solution 
10g SDS  
Dissolved in 100ML 0.01M HCL 
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Appendix 2 
 
2.1. The effect of DMSO on WHCO1 cell viability (One-Way anova and 
Tukey posttest) 
 
Table 1.1.B: One-Way ANOVA column statistics for DMSO treated WHCO1 
cells  
 
  Control 0.2 %V/V 0.5%V/V 1%V/V 2.5%V/V 5%V/V
Number of 
values 3 3 3 3 3 3
0.612 0.528 0.512 0.424 0.337 0.067Minimum 
0.612 0.528 0.512 0.424 0.337 0.06725% Percentile 
0.612 0.548 0.513 0.465 0.346 0.067Median 
0.612 0.569 0.526 0.466 0.346 0.0875% Percentile 
0.612 0.569 0.526 0.466 0.346 0.08Maximum 
              
0.612 0.5483 0.517 0.4517 0.343 0.07133Mean 
0 0.0205 0.00781 0.02397 0.0052 0.00751Std. Deviation 
0 0.01184 0.00451 0.01384 0.003 0.00433Std. Error 
              
0.612 0.4974 0.4976 0.3921 0.3301 0.05269Lower 95% CI 
0.612 0.5993 0.5364 0.5112 0.3559 0.08998Upper 95% CI 
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Table 1.2: Repeated measures ANOVA for DMSO treated WHCO1 cells 
 
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 6
F 503.6
R squared 0.996
    
Was the pairing significantly effective?   
R squared 0.000000772
F 0.0009757
P value 0.999
P value summary ns 
Is there significant matching? (P < 0.05) No 
 
Table 1.3: General ANOVA for DMSO treated WHCO1 cells  
 
 SS df MS 
Treatment (between columns) 0.5735 5 0.1147 
2.20E-
07 Individual (between rows) 4.44E-07 2
Residual (random) 0.002278 10 0.00023 
Total 0.5757 17   
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Table 1.4: Tukey’s multiple comparison test showing the significant difference 
between the different DMSO concentrations used to treat WHCO1 cells 
 
 
 
 
  
 
 
 
 
 
 Mean Diff. q 
Significant? P < 
0.05? Summary 95% CI of diff 
Control vs 0.2 %V/V 0.06367 7.307 Yes ** 0.02087 to 0.1065 
Control vs 0.5%V/V 0.095 10.9 Yes *** 0.05220 to 0.1378 
Control vs 1%V/V 0.1603 18.4 Yes *** 0.1175 to 0.2031 
Control vs 2.5%V/V 0.269 30.87 Yes *** 0.2262 to 0.3118 
Control vs 5%V/V 0.5407 62.05 Yes *** 0.4979 to 0.5835 
0.2 %V/V vs 0.5%V/V 0.03133 3.596 No ns -0.01147 to 0.07413 
0.2 %V/V vs 1%V/V 0.09667 11.09 Yes *** 0.05387 to 0.1395 
0.2 %V/V vs 2.5%V/V 0.2053 23.57 Yes *** 0.1625 to 0.2481 
0.2 %V/V vs 5%V/V 0.477 54.75 Yes *** 0.4342 to 0.5198 
0.5%V/V vs 1%V/V 0.06533 7.498 Yes ** 0.02253 to 0.1081 
0.5%V/V vs 2.5%V/V 0.174 19.97 Yes *** 0.1312 to 0.2168 
0.5%V/V vs 5%V/V 0.4457 51.15 Yes *** 0.4029 to 0.4885 
1%V/V vs 2.5%V/V 0.1087 12.47 Yes *** 0.06587 to 0.1515 
1%V/V vs 5%V/V 0.3803 43.65 Yes *** 0.3375 to 0.4231 
2.5%V/V vs 5%V/V 0.2717 31.18 Yes *** 0.2289 to 0.3145 
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Appendix 3 
3.1 The effect of DMSO on WHCO6 cell viability (One-Way anova and 
Tukey posttest). 
Table 1.5: One-way Anova column statistics for DMSO treated WHCO6 cells 
0.2 
%V/V   Control 0.5%V/V 1%V/V 2.5%V/V 5%V/V
Number of 
values 3 3 3 3 3 3 
0.4007 0.387 0.355 0.326 0.287 0.158 Minimum 
0.4007 0.387 0.355 0.326 0.287 0.158 25% Percentile 
0.4007 0.391 0.365 0.334 0.296 0.159 Median 
0.4007 0.398 0.377 0.335 0.297 0.166 75% Percentile 
0.4007 0.398 0.377 0.335 0.297 0.166 Maximum 
              
0.4007 0.392 0.3657 0.3317 0.2933 0.161 Mean 
0 0.005568 0.01102 0.00493 0.005508 0.00436Std. Deviation 
0 0.003215 0.00636 0.00285 0.00318 0.00252Std. Error 
              
0.4007 0.3782 0.3383 0.3194 0.2797 0.1502 Lower 95% CI 
0.4007 0.4058 0.393 0.3439 0.307 0.1718 Upper 95% CI 
 
Table 1.6: Repeated measures ANOVA for DMSO treated WHCO6 cells 
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 6 
F 689.2 
R squared 0.9971 
    
Was the pairing significantly effective?   
R squared 0.0008797 
F 1.521 
P value 0.265 
P value summary ns 
Is there significant matching? (P < 0.05) No 
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Table 1.7: General ANOVA for DMSO treated WHCO6 cells 
 SS df MS 
Treatment (between columns) 0.1194 5 0.02388 
Individual (between rows) 0.0001054 2 0.00005272 
Residual (random) 0.0003466 10 0.00003466 
Total 0.1199 17   
 
Table 1.8: Tukey’s multiple comparison test showing the significant difference 
between the different DMSO concentrations used to treat WHCO6 cells 
Mean 
Diff. 
Significant? P < 
0.05?  q Summary 95% CI of diff 
Control vs 0.2 %V/V 0.008667 2.55 No ns -0.008028 to 0.02536 
Control vs 0.5%V/V 0.035 10.3 Yes *** 0.01831 to 0.05170 
Control vs 1%V/V 0.069 20.3 Yes *** 0.05231 to 0.08570 
Control vs 2.5%V/V 0.1073 31.58 Yes *** 0.09064 to 0.1240 
Control vs 5%V/V 0.2397 70.51 Yes *** 0.2230 to 0.2564 
0.2 %V/V vs 
0.5%V/V 0.02633 7.748 Yes ** 0.009638 to 0.04303 
0.2 %V/V vs 1%V/V 0.06033 17.75 Yes *** 0.04364 to 0.07703 
0.2 %V/V vs 
2.5%V/V 0.09867 29.03 Yes *** 0.08197 to 0.1154 
0.2 %V/V vs 5%V/V 0.231 67.96 Yes *** 0.2143 to 0.2477 
0.5%V/V vs 1%V/V 0.034 10 Yes *** 0.01730 to 0.05069 
0.5%V/V vs 2.5%V/V 0.07233 21.28 Yes *** 0.05564 to 0.08903 
0.5%V/V vs 5%V/V 0.2047 60.22 Yes *** 0.1880 to 0.2214 
1%V/V vs 2.5%V/V 0.03833 11.28 Yes *** 0.02164 to 0.05503 
1%V/V vs 5%V/V 0.1707 50.21 Yes *** 0.1540 to 0.1874 
2.5%V/V vs 5%V/V 0.1323 38.94 Yes *** 0.1156 to 0.1490 
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Appendix 4 
4.1 The effect of BNF on WHCO1 cell proliferation (One-way anova and 
Tukey posttest) 
Table 1.9: One-way ANOVA column statistics for WHCO1 cells treated with 
BNF for 24 hours 
 
 Control 5µM 10µM 25µM 50µM 100µM 
Number of 
values 3 3 3 3 3 3
1.04 0.9387 0.8637 0.5657 0.5057 0.4557Minimum 
1.04 0.9387 0.8637 0.5657 0.5057 0.455725% Percentile 
1.04 0.9917 0.9087 0.5667 0.5177 0.4617Median 
1.04 0.9917 0.9217 0.5687 0.5207 0.483775% Percentile 
1.04 0.9917 0.9217 0.5687 0.5207 0.4837Maximum 
              
1.04 0.974 0.898 0.567 0.5147 0.467Mean 
0 0.0306 0.03044 0.00153 0.00794 0.01474Std. Deviation 
0 0.01767 0.01757 0.00088 0.00458 0.00851Std. Error 
              
1.04 0.898 0.8224 0.5632 0.4949 0.4304Lower 95% CI 
1.04 1.05 0.9736 0.5708 0.5344 0.5036Upper 95% CI 
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Table 1.10: Repeated measures ANOVA for WHCO1 cells treated with BNF 
for 24 hours 
 
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 6 
F 474.9 
R squared 0.9958 
    
Was the pairing significantly effective?   
R squared 0.0001873 
F 0.2233 
P value 0.8037 
P value summary ns 
Is there significant matching? (P < 0.05) No 
 
Table 1.11: General ANOVA for WHCO1 cells treated with BNF for 24 hours  
 
 SS df MS 
Treatment (between 
columns) 0.9752 5 0.195
Individual (between rows) 0.00018 2 9.17E-05
Residual (random) 0.00411 10 0.000411
Total 0.9795 17   
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Table 1.12: Tukey’s multiple comparison test showing the significant 
difference between the different BNF concentrations used to treat WHCO1 
cells after 24 hours 
Mean 
Diff. 
Significant? P < 
0.05?  q Summary 95% CI of diff 
Control vs 5M 0.06633 5.669 Yes * 0.008860 to 0.1238 
Control vs 10M 0.1423 12.16 Yes *** 0.08486 to 0.1998 
Control vs 25M 0.4733 40.45 Yes *** 0.4159 to 0.5308 
Control vs 50M 0.5257 44.93 Yes *** 0.4682 to 0.5831 
Control vs 100M 0.5733 49 Yes *** 0.5159 to 0.6308 
5M vs 10M 0.076 6.495 Yes ** 0.01853 to 0.1335 
5M vs 25M 0.407 34.78 Yes *** 0.3495 to 0.4645 
5M vs 50M 0.4593 39.26 Yes *** 0.4019 to 0.5168 
            
5M vs 100M 0.507 43.33 Yes *** 0.4495 to 0.5645 
10M vs 25M 0.331 28.29 Yes *** 0.2735 to 0.3885 
10M vs 50M 0.3833 32.76 Yes *** 0.3259 to 0.4408 
10M vs 100M 0.431 36.84 Yes *** 0.3735 to 0.4885 
25M vs 50M 0.05233 4.473 No ns -0.005140 to 0.1098 
25M vs 100M 0.1 8.547 Yes ** 0.04253 to 0.1575 
 
50M vs 100M 0.04767 4.074 No ns -0.009807 to 0.1051 
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Table 1.13: One-way ANOVA column statistics for WHCO1 cells treated with 
BNF for 48 hours 
48H BNF  Control 5µM 10µM 25µM 50µM 100µM 
3 3 3 3 3 3Number of values 
1.608 1.469 1.392 0.97 0.9028 0.9503Minimum 
1.608 1.469 1.392 0.97 0.9028 0.950325% Percentile 
1.608 1.543 1.414 0.971 0.9847 0.974Median 
1.608 1.578 1.46 0.9752 0.9954 0.9875% Percentile 
1.608 1.578 1.46 0.9752 0.9954 0.98Maximum 
         
1.608 1.53 1.422 0.9721 0.961 0.9681Mean 
0 0.05592 0.03508 0.00276 0.05063 0.01572Std. Deviation 
0 0.03228 0.02025 0.00159 0.02923 0.00908Std. Error 
         
1.608 1.391 1.335 0.9652 0.8352 0.929Lower 95% CI 
1.608 1.669 1.509 0.9789 1.087 1.007Upper 95% CI 
 
Table 1.14: Repeated measures ANOVA statistics for WHCO1 cells treated 
with BNF for 48 hours 
 
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 6 
F 288.9 
R squared 0.9931 
    
Was the pairing significantly effective?   
R squared 0.003087 
F 2.252 
P value 0.1558 
P value summary ns 
Is there significant matching? (P < 0.05) No 
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Table 1.15: General ANOVA statistics for WHCO1 cells treated with BNF for 
48 hours 
 
SS df MS  
Treatment (between 
columns) 1.429 5 0.2858 
Individual (between rows) 0.004456 2 0.002228 
Residual (random) 0.009895 10 0.0009895 
Total 1.443 17   
 
Table 1.16: Tukey’s multiple comparison test showing the significant 
difference between the different BNF concentrations used to treat WHCO1 
cells after 48 hours 
 
 
 
 
 Mean Diff. q 
Significant? P < 
0.05? Summary 95% CI of diff 
Control vs 5M 0.07845 4.319 No ns -0.01076 to 0.1677 
Control vs 10M 0.1863 10.26 Yes *** 0.09705 to 0.2755 
Control vs 25M 0.6363 35.03 Yes *** 0.5471 to 0.7255 
Control vs 50M 0.6474 35.65 Yes *** 0.5582 to 0.7366 
Control vs 100M 0.6402 35.25 Yes *** 0.5510 to 0.7294 
5M vs 10M 0.1078 5.937 Yes * 0.01861 to 0.1970 
5M vs 25M 0.5578 30.72 Yes *** 0.4686 to 0.6470 
5M vs 50M 0.5689 31.33 Yes *** 0.4797 to 0.6581 
5M vs 100M 0.5618 30.93 Yes *** 0.4726 to 0.6510 
10M vs 25M 0.45 24.78 Yes *** 0.3608 to 0.5392 
10M vs 50M 0.4611 25.39 Yes *** 0.3719 to 0.5503 
10M vs 100M 0.454 25 Yes *** 0.3648 to 0.5432 
25M vs 50M 0.0111 0.611 No ns -0.07811 to 0.1003 
25M vs 100M 0.003957 0.218 No ns -0.08525 to 0.09316 
50M vs 100M -0.007144 0.393 No ns -0.09635 to 0.08206 
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Table 1.17: One-way ANOVA column statistics for WHCO1 cells treated with 
BNF for 72 hours 
 
72H BNF  Control 5µM 10µM 25µM 50µM 100µM 
3 3 3 3 3 3Number of values 
1.668 1.664 1.676 1.264 1.181 1.135Minimum 
1.668 1.664 1.676 1.264 1.181 1.13525% Percentile 
1.668 1.715 1.676 1.264 1.231 1.161Median 
1.668 1.715 1.726 1.278 1.246 1.17375% Percentile 
1.668 1.715 1.726 1.278 1.246 1.173Maximum 
         
1.668 1.698 1.692 1.268 1.219 1.156Mean 
0 0.02944 0.02887 0.00808 0.03403 0.01943Std. Deviation 
0 0.017 0.01667 0.00467 0.01965 0.01122Std. Error 
         
1.668 1.625 1.621 1.248 1.134 1.108Lower 95% CI 
1.668 1.771 1.764 1.288 1.304 1.204Upper 95% CI 
 
Table 1.18: Repeated measures ANOVA for WHCO1 cells treated with BNF 
for 72 hours 
 
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 6 
F 327.6 
R squared 0.9939 
    
Was the pairing significantly effective?   
R squared 0.0003594 
F 0.2963 
P value 0.7499 
P value summary ns 
Is there significant matching? (P < 0.05) No 
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Table 1.19: General ANOVA for WHCO1 cells treated with BNF for 72 hours 
 
 
 SS df MS 
Treatment (between columns) 1.021 5 0.2042 
Individual (between rows) 0.0003693 2 0.0001847 
Residual (random) 0.006233 10 0.0006233 
Total 1.028 17   
 
Table 1.20: Tukey’s multiple comparison test showing the significant 
difference between the different BNF concentrations used treat WHCO1 cells 
for 72 hours 
Mean 
Diff. 
Significant? P < 
0.05?  q Summary 95% CI of diff 
Control vs 5M -0.02967 2.058 No ns -0.1005 to 0.04114 
Control vs 10M -0.02433 1.688 No ns -0.09514 to 0.04647 
Control vs 25M 0.3997 27.73 Yes *** 0.3289 to 0.4705 
Control vs 50M 0.449 31.15 Yes *** 0.3782 to 0.5198 
Control vs 100M 0.512 35.52 Yes *** 0.4412 to 0.5828 
5M vs 10M 0.005333 0.37 No ns -0.06547 to 0.07614 
5M vs 25M 0.4293 29.78 Yes *** 0.3585 to 0.5001 
5M vs 50M 0.4787 33.21 Yes *** 0.4079 to 0.5495 
5M vs 100M 0.5417 37.58 Yes *** 0.4709 to 0.6125 
10M vs 25M 0.424 29.41 Yes *** 0.3532 to 0.4948 
10M vs 50M 0.4733 32.84 Yes *** 0.4025 to 0.5441 
10M vs 100M 0.5363 37.21 Yes *** 0.4655 to 0.6071 
25M vs 50M 0.04933 3.422 No ns -0.02147 to 0.1201 
25M vs 100M 0.1123 7.793 Yes ** 0.04153 to 0.1831 
 
50M vs 100M 0.063 4.371 No ns -0.007804 to 0.1338 
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Appendix 5 
5.1 The effect of BNF on WHCO6 cell proliferation (One-way anova and 
Tukey posttest) 
Table 1.21: One-way ANOVA column statistics for WHCO6 cells treated with 
BNF for 24 hours 
 Control 5µM 10µM 25µM 50µM 100µM 
3 3 3 3 3 3 Number of values 
0.7955 0.7305 0.6435 0.5275 0.5015 0.5155 Minimum 
0.7955 0.7305 0.6435 0.5275 0.5015 0.5155 25% Percentile 
0.7955 0.7375 0.6475 0.5305 0.5045 0.5175 Median 
0.7955 0.7425 0.648 0.5415 0.5175 0.5215 75% Percentile 
0.7955 0.7425 0.648 0.5415 0.5175 0.5215 Maximum 
              
0.7955 0.7368 0.6463 0.5332 0.5078 0.5182 Mean 
0 0.00603 0.00247 0.00737 0.00851 0.00306Std. Deviation 
0 0.00348 0.00143 0.00426 0.00491 0.00176Std. Error 
              
0.7955 0.7219 0.6402 0.5149 0.4867 0.5106 Lower 95% CI 
0.7955 0.7518 0.6525 0.5515 0.529 0.5258 Upper 95% CI 
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Table 1.22: Repeated measures ANOVA for WHCO6 cells treated with BNF 
for 24 hours 
 
P value P<0.0001
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 6 
F 1441 
R squared 0.9986 
    
Was the pairing significantly effective?   
R squared 0.00019 
F 0.6711 
P value 0.5327 
P value summary ns 
Is there significant matching? (P < 0.05) No 
 
Table 1.23: General ANOVA for WHCO6 cells treated with BNF for 24 hours 
 
ANOVA Table SS df MS 
Treatment (between 
columns) 0.2267 5 0.04535
Individual (between rows) 4.2E-05 2 2.1E-05
Residual (random) 0.00031 10 3.1E-05
Total 0.2271 17   
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Table 1.24: Tukey’s multiple comparison test showing the significant 
difference between the different BNF concentrations used to treat WHCO6 
cells for 24 hours 
 
 Mean Diff. q 
Significant? P < 
0.05? Summary 95% CI of diff 
Control vs 5M 0.05867 18.12 Yes *** 0.04276 to 0.07457 
Control vs 10M 0.1492 46.06 Yes *** 0.1333 to 0.1651 
Control vs 25M 0.2623 81.01 Yes *** 0.2464 to 0.2782 
Control vs 50M 0.2877 88.83 Yes *** 0.2718 to 0.3036 
Control vs 100M 0.2773 85.64 Yes *** 0.2614 to 0.2932 
5M vs 10M 0.0905 27.95 Yes *** 0.07459 to 0.1064 
5M vs 25M 0.2037 62.89 Yes *** 0.1878 to 0.2196 
5M vs 50M 0.229 70.71 Yes *** 0.2131 to 0.2449 
5M vs 100M 0.2187 67.52 Yes *** 0.2028 to 0.2346 
10M vs 25M 0.1132 34.95 Yes *** 0.09726 to 0.1291 
10M vs 50M 0.1385 42.77 Yes *** 0.1226 to 0.1544 
10M vs 100M 0.1282 39.58 Yes *** 0.1123 to 0.1441 
25M vs 50M 0.02533 7.823 Yes ** 0.009426 to 0.04124 
25M vs 100M 0.015 4.623 No ns -0.0009070 to 0.03091 
50M vs 100M -0.01033 3.191 No ns -0.02624 to 0.005574 
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Table 1.25: One-way ANOVA column statistics for WHCO6 cells treated with 
BNF for 48 hours 
 
 Control 5µM 10µM 25µM 50µM 100µM 
Number of 
values 3 3 3 3 3 3
Minimum 0.9363 0.8732 0.5039 0.4511 0.4068 0.3836
25% Percentile 0.9363 0.8732 0.5039 0.4511 0.4068 0.3836
Median 0.9363 0.8832 0.5086 0.4562 0.4349 0.3963
75% Percentile 0.9363 0.8845 0.509 0.4613 0.4559 0.3998
Maximum 0.9363 0.8845 0.509 0.4613 0.4559 0.3998
              
Mean 0.9363 0.8803 0.5072 0.4562 0.4325 0.3932
Std. Deviation 0 0.00617 0.00285 0.00511 0.02463 0.0085
Std. Error 0 0.00357 0.00165 0.00295 0.01422 0.00491
              
Lower 95% CI 0.9363 0.865 0.5001 0.4435 0.3713 0.3721
Upper 95% CI 0.9363 0.8956 0.5143 0.4689 0.4937 0.4143
 
Table 1.26: Repeated measures ANOVA for WHCO6 cells treated with BNF 
for 48 hours 
 
P value P<0.0001 
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 6 
F 1617 
R squared 0.9988 
    
Was the pairing significantly effective?   
R squared 0.000479 
F 1.938 
P value 0.1945 
P value summary ns 
Is there significant matching? (P < 0.05) No 
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Table 1.27: General ANOVA for WHCO6 cells treated with BNF for 48 hours 
 
 SS df MS 
Treatment (between 
columns) 0.8754 5 0.1751
Individual (between rows) 0.00042 2 0.00021
Residual (random) 0.00108 10 0.00011
Total 0.8769 17   
 
Table 1.28: Tukey’s multiple comparison test showing the significant 
difference between the different BNF concentrations used to treat WHCO6 
cells for 48 hours 
 
 Mean Diff. q 
Significant? P < 
0.05? Summary 95% CI of diff 
Control vs 5M 0.05603 9.326 Yes *** 0.02652 to 0.08554 
Control vs 10M 0.4292 71.43 Yes *** 0.3996 to 0.4587 
Control vs 25M 0.4802 79.92 Yes *** 0.4506 to 0.5097 
Control vs 50M 0.5038 83.86 Yes *** 0.4743 to 0.5333 
Control vs 100M 0.5431 90.39 Yes *** 0.5136 to 0.5726 
5M vs 10M 0.3731 62.1 Yes *** 0.3436 to 0.4026 
5M vs 25M 0.4241 70.59 Yes *** 0.3946 to 0.4536 
5M vs 50M 0.4478 74.53 Yes *** 0.4183 to 0.4773 
5M vs 100M 0.4871 81.07 Yes *** 0.4576 to 0.5166 
10M vs 25M 0.05099 8.487 Yes ** 0.02148 to 0.08050 
10M vs 50M 0.07466 12.43 Yes *** 0.04515 to 0.1042 
10M vs 100M 0.1139 18.96 Yes *** 0.08443 to 0.1435 
25M vs 50M 0.02367 3.94 No ns -0.005842 to 0.05318 
25M vs 100M 0.06295 10.48 Yes *** 0.03344 to 0.09247 
50M vs 100M 0.03928 6.538 Yes ** 0.009772 to 0.06880 
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Table 1.29:  One-way ANOVA column statistics for WHCO6 cells treated 
with BNF for 72 hours 
 
Contro
l 72h BNF 5µM 10µM 25µM 50µM 100µM 
Number of 
values 3 3 3 3 3 3 
Minimum 1.135 1 0.637 0.423 0.375 0.314 
25% Percentile 1.135 1 0.637 0.423 0.375 0.314 
Median 1.135 1.025 0.688 0.446 0.377 0.332 
75% Percentile 1.135 1.035 0.688 0.478 0.394 0.34 
Maximum 1.135 1.035 0.688 0.478 0.394 0.34 
              
Mean 1.135 1.02 0.671 0.449 0.382 0.3287 
Std. Deviation 0 0.01803 0.02944 0.02762 0.01044 0.01332 
0.00602
8 
0.00768
8 Std. Error 0 0.01041 0.017 0.01595
              
Lower 95% CI 1.135 0.9752 0.5979 0.3804 0.3561 0.2956 
Upper 95% CI 1.135 1.065 0.7441 0.5176 0.4079 0.3617 
 
Table 1.30: Repeated measures ANOVA for WHCO6 cells treated with BNF 
for 72 hours 
P value P<0.0001
P value summary *** 
Are means signif. different? (P < 0.05) Yes 
Number of groups 6 
F 945.8 
R squared 0.9979 
    
Was the pairing significantly effective?   
R squared 0.000432 
F 1.024 
P value 0.3939 
P value summary ns 
Is there significant matching? (P < 0.05) No 
  
123 
 
Table 1.31: General ANOVA for WHCO6 cells treated with BNF for 72 hours 
 
 SS df MS 
Treatment (between columns) 1.76 5 0.3519 
Individual (between rows) 0.000762 2 0.000381 
Residual (random) 0.003721 10 0.000372 
Total 1.764 17   
 
Table 1.32: Tukey’s multiple comparison test showing the significant 
difference between the different BNF concentrations used to treat WHCO6 
cells for 72 hours 
Tukey's Multiple 
Comparison Test 
Significant? P < 
0.05? Mean Diff. q Summary 95% CI of diff 
Control vs 5M 0.1147 10.3 Yes *** 0.05997 to 0.1694 
Control vs 10M 0.4637 41.64 Yes *** 0.4090 to 0.5184 
Control vs 25M 0.6857 61.57 Yes *** 0.6310 to 0.7404 
Control vs 50M 0.7527 67.59 Yes *** 0.6980 to 0.8074 
Control vs 100M 0.806 72.38 Yes *** 0.7513 to 0.8607 
5M vs 10M 0.349 31.34 Yes *** 0.2943 to 0.4037 
5M vs 25M 0.571 51.27 Yes *** 0.5163 to 0.6257 
5M vs 50M 0.638 57.29 Yes *** 0.5833 to 0.6927 
5M vs 100M 0.6913 62.08 Yes *** 0.6366 to 0.7460 
10M vs 25M 0.222 19.93 Yes *** 0.1673 to 0.2767 
10M vs 50M 0.289 25.95 Yes *** 0.2343 to 0.3437 
10M vs 100M 0.3423 30.74 Yes *** 0.2876 to 0.3970 
25M vs 50M 0.067 6.016 Yes * 0.01230 to 0.1217 
25M vs 100M 0.1203 10.81 Yes *** 0.06563 to 0.1750 
50M vs 100M 0.05333 4.789 No ns -0.001368 to 0.1080 
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Appendix 6 
6.1 The median inhibition concentration (IC ) values 50
Table 1.33: The median inhibition concentration (IC50) values of BNF in 
WHCO1 cells 
 
BNF 
CONC Absorbance values Percentage Average IC STDEV 50
0µM 1.040334 1.040334 1.040334 100 100 100 100   0 
5µM 0.938667 0.991667 0.991667 90.22747 95.32198 95.32198 93.62381   2.941321 
10µM 0.921667 0.863667 0.908667 88.59337 83.01824 87.34378 86.31846  2.925572 
25µM 0.566667 0.568667 0.565667 54.46972 54.66196 54.3736 54.50176 ~ 25µM 0.14683 
50µM 0.505667 0.520667 0.517667 48.60622 50.04806 49.75969 49.47132   0.762952 
100µM 0.461667 0.483667 0.455667 44.37681 46.49151 43.80007 45.43416   1.417067 
 
Table 1.34: The median inhibition concentration (IC50) values of BNF in 
WHCO6 cells 
BNF 
CONC Absorbance values Percentage Average IC STDEV 50
0µM 0.936333 0.936333 0.936333 0.93633 100 100 100 100 100   0 
5µM 0.884473 0.873209 0.883224   94.46137 93.2584 94.328   94.01591   0.659422 
10µM ~10µM 0.508988 0.503887 0.489733 0.50864 54.35972 53.8149 52.3033 54.3231 53.70025 0.9639 
25µM 0.451072 0.456183 0.461294   48.17431 48.7202 49.266   48.72017   0.545853 
50µM 0.45609 0.406796 0.434851 0.45589 48.71023 43.4457 46.4419 48.6891 46.82172   2.489687 
100µM 
 
0.430515 0.383627 0.396276 0.39978 45.97883 40.9712 42.3221 42.6967 42.99221   2.124516 
 
 
Note: The one-way anova results for the other compounds are not shown. 
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Appendix 7 
 
7.1. Protein extraction 
 
Laemmli sample buffer 
1.5% Tris.HCL (pH 6.8) 
2% SDS 
10% Glycerol 
5% β-mercaptoethanol 
Make up in dH2O 
Store at 4ºC 
 
7.2 Protein estimation 
 
Trichloroacetic acid (TCA) 
 
7.5% TCA 
Make up to the required volume with dH2O 
 
Coomassie Blue solution (0.25%) 
 
0.25% Coomassie brilliant blue powder 
50% Methanol 
10% Glacial acetic acid 
Make up to final volume with dH2O 
 
Destaining solution 
 
12% Glacial acetic acid 
10% Methanol 
Make up to final volume with dH2O 
 
Elution solution 
 
66% Methanol 
33% dH2O 
1% Ammonia 
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Estimation of the total protein content of cells 
 
Protein Estimation Standard currve
y = 0.0102x + 0.013
R2 = 0.9965
0
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Figure 7.1: BSA standard curve for protein estimation. Shown is a plot of the 
absorbance values at 596nm versus BSA concentrations (1-20µg). The equation of the standard 
curve(y=0.0102x + 0.013) was used to calculate the unknown concentrations of the whole cell 
extracts. R2 (Linear regression) =0.9965. 
 
7.3 SDS-PAGE 
 
Separating gel 
 
10% Acrylamide 
0.1% NN’-methylenebisacrylamide 
375 mM Tris-HCl, pH 8.8 
0.2% SDS 
Make up to final volume with dH2O 
Just before use add: 
1mM Ammonium persulphate 
0.25% N, N, N’N’-tetramethylenediamine (TEMED) 
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Stacking gel 
 
10% Acrylamide 
0.1% NN’-methylenebisacrylamide 
125 mM Tris-HCl, pH 6.8 
0.2% SDS 
Make up to final volume with dH2O 
Just before use add: 
1mM Ammonium persulphate 
0.25% TEMED 
 
Running buffer 
 
3.74 mM SDS 
25 mM Tris-HCl, pH 8.3 
192.5 mM Glycine 
Make up to final volume with dH2O 
 
 Destain solution 
 
10% Acetic acid 
10% Methanol 
Make up to final volume with dH2O 
7.4 Western Blot 
 
Transfer buffer 
 
25 mM Tris-HCl, pH 8.3 
1.41% Glycine 
20% Methanol 
 
Make up to final volume with dH2O (Store at4ºc)  
Blocking solution 
 
50 mM Tris-HCl, pH 7.8 
2 mM Calcium chloride dihydrate 
5% non-fat milk powder 
0.01% anti-foam 
0.05% Triton-X 100 
Make up to final volume with dH2O 
Store at 4ºC 
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Super signal west pico chemiluminescent substrate kit 
 
Before use mix: 
50% Luminol/Enhancer solution 
50% Stable peroxide buffer 
Store in the dark 
 
Developer 
 
6.4 M Metol 
0.6 M Sodium sulphite (anhydrous) 
80 mM Hydroquinine 
0.45 mM Sodium carbonate (anhydrous) 
34 mM Potassium bromide 
Make up to final volume with dH2O 
Store in the dark 
 
Fixer 
 
0.8 M Sodium trisulphate 
0.2 M Sodium metasulphite 
Make up to final volume with dH2O 
Store in the dark 
 
 
 
 
129 
 
Appendix 8 
 
8.1 T-test results for comparing protein expression level 
 
Table 1.35: CYP1A1 fold induction 
 
 
 WHCO1 BNF treatment WHCO6 BNF treatment 
Fold 
induction 
 1.348312 1.327196  1.098469 1.075601 1.075601
Fold 
induction  
average 1.337754 1.083224 
 
STDEV 0.014931 0.013203 
 
P 0.019894 0.008285 
 
Table 1.36:CYP1A2 fold induction 
 
 
 WHCO1 BNF treatment WHCO6 BNF treatment 
Fold induction 
 1.352497 1.36784  1.476955 1.399223  
Fold induction 
average 1.360169 1.438089 
 
STDEV 0.010849 0.054965 
 
P 0.013558 0.056332 
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Table 1.37:CYP1B1 fold induction 
 
 
 WHCO1 BNF treatment WHCO6 BNF treatment 
Fold 
induction 
 2.467483 2.276516 2.517369 1.676021 1.794708  
Fold 
induction 
average 2.420456 1.735364 
 
STDEV 0.127127 0.083925 
 
P 0.002659 0.051264 
 
Table 1.38: AHR fold induction 
 
 
 WHCO1 BNF treatment WHCO6 BNF treatment 
Fold induction 
 0.751155 0.722407 0.768886 0.22846 0.218438  
Fold induction 
average 0.747483 0.223449 
 
STDEV 0.023456 0.007087 
 
P 0.002864 0.004108 
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